| Written | 2020-03 | Catarina Sofia Mateus Reis Silva, Gabriel Henrique Barbosa, Paola Cristina Branco, Paula Christine Jimenez, João Agostinho Machado-Neto, Letícia Veras Costa-Lotufo |
| Department of Pharmacology, Institute of Biomedical Sciences of the University of Sao Paulo, Sao Paulo, Brazil (CSMRS, PCB, JAMN, LVCL); Department of Marine Science, Institute of Marine Sciences, Federal University of Sao Paulo, Santos, Brazil (GHB, PCJ); reis.catarinasofia@gmail.com, ghb20@gmail.com. pbranco@usp.br, pcjimenez@unifesp.br, jamachadoneto@usp.br, costalotufo@usp.br |
| Abstract | X-linked inhibitor of apoptosis (XIAP), also referred to as BIRC4 or IAP3, is one of the most studied members among the proteins known as Inhibitors of Apoptosis Proteins (IAPs). This protein family portrays its main role by preventing apoptotic cell death through direct or indirect inhibition of caspase activity. All members of the IAPs carry at least one BIR domain in their structure, which are generally responsible for caspase interaction. XIAP has three BIR domains, enabling interaction with both initiation and effector caspases. Moreover, it is also structured with a RING finger domain, which functions as a ubiquitin ligase (E3), and one UBA domain, for binding to ubiquitin, further rendering XIAP a central role in the ubiquitination process and, thus, implicating such IAP in multiple signaling pathways, including cell death, autophagy, immunity, inflammation, cell cycle, and cell migration. XIAP overexpression is found in a variety of cancer types and is frequently associated with chemoresistance and increased risk of relapse. Furthermore, there are many evidences that XIAP inhibition may sensitize tumor cells to chemotherapy agents, which make this protein a potential target in cancer. |
| Keywords | XIAP; Interact with caspases; Apoptosis; Bladder cancer; Brain cancer; Breast cancer; Cervical carcinoma; Colorectal cancer; Esophageal cancer; Gastric cancer; Head and neck squamous cell carcinoma; Kidney cancer; Leukemia; Liver cancer; Lung cancer; Lymphoma; Medulloblastoma; Melanoma; Multiple myeloma; Neuroblastoma; Oral cancer; Osteosarcoma; Ovarian cancer; Pancreatic Cancer; Prostate cancer; Thyroid cancer; Funding: Process numbers: 2018/06522-2, 2017/09022-8 and 2015/17177-6, Fundao de Amparo à Pesquisa do Estado de São Paulo (FAPESP) and Coordenao de Aperfeiçoamento de Pessoal de Nível Superior (CAPES). |
| Identity |
| Alias (NCBI) | X-Linked Inhibitor of Apoptosis, E3 Ubiquitin Protein Ligase | Baculoviral IAP Repeat-Containing Protein 4 | RING-Type E3 Ubiquitin Transferase XIAP | E3 Ubiquitin-Protein Ligase XIAP | Inhibitor of Apoptosis Protein 3 | IAP-Like Protein 1 | IAP-Like Protein | X-Linked IAP | hIAP-3 | hIAP3 | BIRC4 | IAP-3 | API3 | ILP1 | MIHA | XLP2 |
| HGNC (Hugo) | XIAP |
| HGNC Alias symb | hILP | ILP-1 |
| HGNC Alias name | IAP-like protein 1 |
| HGNC Previous name | API3 | BIRC4 |
| HGNC Previous name | "baculoviral IAP repeat-containing 4 | X-linked inhibitor of apoptosis, E3 ubiquitin protein ligase" |
| LocusID (NCBI) | 331 |
| Atlas_Id | 796 |
| Location | Xq25 [Link to chromosome band Xq25] |
| Location_base_pair | Starts at 123859812 and ends at 123913979 bp from pter ( according to GRCh38/hg38-Dec_2013) [Mapping XIAP.png] |
| Fusion genes (updated 2017) | Data from Atlas, Mitelman, Cosmic Fusion, Fusion Cancer, TCGA fusion databases with official HUGO symbols (see references in chromosomal bands) |
| DNA/RNA |
| Description | The entire XIAP gene is approximately 54.2 Kb (start: 123859724 bp; end: 123913979 bp; orientation: plus strand). There are two transcript variants deposited in the NCBI database (https://www.ncbi.nlm.nih.gov/gene). The transcript variant 1 is the longest transcript (cDNA: 8460 bp), while transcript variant 2 differs in the 5' UTR, compared to transcript variant 1 (cDNA: 8427 bp); however, both transcripts encode the same protein (497 aa). There are nine additional transcript variants reported in Ensembl (http://www.ensembl.org/): a transcript variant containing 8415 bp, which generates a protein of 497 aa; a transcript variant containing 528 bp, which generates a protein of 156 aa; a transcript variant containing 390 bp, which generates a protein of 16 aa; and six long non-coding RNA-related transcripts that do not generate proteins (764, 628, 598, 533, 495 and 157 bp). |
| Protein |
 | |||||||||||||||||||||||||||||||||||||||||
| XIAP protein structure. XIAP (also known as BIRC4 or IAP3) presents two transcripts variants deposited in NCBI database. The protein structure presents 497 amino acids (aa) and is composed of three BIR domain being one of them that responsible for its anti-apoptotic activity, one RING zinc finger domain and an UBA domain. The XIAP structure containing their domains and the specific interactions of each domain, signaling the importance of XIAP in apoptotic pathways through interaction with caspases. The aa positions are indicated. | |||||||||||||||||||||||||||||||||||||||||
| Description | X-linked inhibitor of apoptosis (XIAP), also referred to as BIRC4, belongs to a family of proteins known as Inhibitors of Apoptosis Proteins (IAPs). This protein family is recognized, mainly, for inhibiting caspase activity, either directly or indirectly, thus preventing apoptotic cell death. Such propriety is generally associated to their distinctive BIR (baculovirus IAP repeat) domain, a conserved sequence of nearly 80 amino acids with a centered Zn+2, which may occur in numbers of one or three among members of this family. In fact, eight human IAPs have been described so far: BIRC1 ( NAIP), BIRC2 (cIAP1), BIRC3 (cIAP2), BIRC4 (XIAP), BIRC5 (Survivin), BIRC6 (Bruce), BIRC7 (Livin) and BIRC8 (ILP-2) (Silke and Vucic, 2014). XIAP presents three BIR domains located at the N-terminus region as demonstrated in Figure 1. Despite similarities shared among BIR domains, their functions may vary according to the IAP member. BIR1 interacts with proteins that modulate NFKB1 (NFκB) signaling (Lu et al., 2007). BIR2 and the linker region between BIR1 and BIR2 domain are necessary for inhibition of effector CASP3 and CASP7 (caspases-3 and -7) (Suzuki et al., 2001). BIR3 domain is responsible for inhibiting CASP9 (caspase-9), thus, preventing the intrinsic apoptosis pathway (Lukacs et al., 2013). By contrast, diablo IAP-binding mitochondrial protein binds to both BIR2 and BIR3 domains, thus inhibiting their function, increasing the activation of CASP3, CASP7 and CASP9 (caspases-3, -7 and -9), and promoting apoptosis (Suzuki et al., 2001, Obexer and Ausserlechner, 2014). At its C-terminus region, XIAP carries a RING zinc finger domain. Although a BIR domain occurs among all IAPs, the RING domain, in turn, is found only in XIAP, BIRC2 and BIRC3. For XIAP, the RING domain involves an E3 ligase effect, indicating an important activity on protein ubiquitin process (Nakatani et al., 2013). Additionally, the RING domain was shown to be involved in NFKB1 signaling and MYC proto-oncogene stability, contributing to cancer progression (Jiang et al., 2019), and also on the migratory and invasive potential of cancer cells (Liu et al., 2012). | ||||||||||||||||||||||||||||||||||||||||
| Expression | Vischioni and colleagues (2006) assessed XIAP expression in a variety of normal adult human tissues in an extensive study using immunohistochemistry, where it displayed an heterogenous pattern. Higher intensity immunoreactivity was mainly observed in the small intestine (specifically in Paneth cells and absorptive epithelium) and in epidermal keratinocytes within all the layers of the skin (except in stratum corneum). XIAP also displayed considerable immunoreactivity in specific areas of the stomach, large intestine, thymus, testicles, ovary and mammary gland. It has been found in a gradient within tissues such as squamous epithelia and in more differentiated cells in other tissues like esophageal epithelium (Vischioni et al., 2006). Indeed, the expression of XIAP is not limited to cell types that are constantly undergoing apoptosis or tissues with faster cell turnover. Given that the main function of XIAP is to impair both intrinsic and extrinsic apoptosis pathways, this finding is of particular interest in oncology research, as mechanisms to avoid cell death are one of the main factors that contribute to the formation of solid tumor masses. Not coincidentally, upregulating XIAP expression is one of the means by which tumor cells may accomplish such resistance. Therefore, XIAP expression levels may directly determine the sensitivity of tumor cells to apoptosis (Eckelman et al., 2006; Yang et al., 2018). XIAP was found to be overexpressed in a variety of cancer types and is frequently associated with chemoresistance and increased risk of recurrence, being, generally, a predictive marker of poor prognosis of the disease (Srinivasula & Ashwell., 2008; Obexer & Ausserlechner, 2014). In this matter, Gao and colleagues (2019) conducted a systematic review and metanalysis to determine the prognostic value of XIAP in patients with different tumor types. The analysis included 40 articles and more than 6,500 patients and concluded that the majority of the studies correlated high XIAP expression levels to an unfavorable prognostic factor for clinical outcomes in cancer patients (Gao et al., 2019). However, some discrepancies have been noted, as higher XIAP levels was also correlated to longer overall survival in non-small cell lung cancer patients (Ferreira et al., 2001b). Additionally, XIAP expression did not show any prognostic significance in cervical carcinoma (Liu et al., 2001) nor was that able to predict the response to chemotherapy in patients with advanced NSCLC (Ferreira et al., 2001a) . An extensive study was conducted by Hussain and colleagues (2017) to assess the expression of XIAP in over 1000 Middle Eastern breast cancer cases by immunohistochemistry, and found this IAP to be overexpressed in 29.5% of the cases with an association to tumor size, extra nodal extension, triple negative breast cancer and poorly differentiated breast cancer subtype (Hussain et al., 2017). Expression and clinical significance of XIAP in a wide variety of cancer was further assessed and demonstrated in ovarian, lung, colorectal, thyroid, prostate, cervical, melanoma, salivary gland, pancreatic, cervical cancers, kidney, liver, neuroblastoma, oral, among others. Some of these will be further discussed herein. XIAP expression was shown to be regulated at multiple levels, including transcriptional, post-transcriptional and translationally regulation. Transcriptional activation of XIAP may be controlled via NFkB pathway and ATP7A (ATPase copper transporting alpha) (Karin & Lin, 2002; Dai et al., 2005; Evans et al., 2018). XIAP protein but not its mRNA was found to be highly increased in childhood acute lymphoblastic leukemia compared to control bone marrow mononuclear cells, and no correlation between protein levels and mRNA was seen either, indicating post-transcriptional regulation (Hundsdoerfer et al., 2010). XIAP expression may also be regulated by an alternative translation initiation by a 162-nucleotide internal ribosome entry site (IRES) located in the 5' untranslated region of XIAP mRNA (Holcik et al., 1999; Holcik & Korneluk, 2000). In addition, different expression levels in normal cells of the same lineage in different organs indicates that IAP expression is also influenced by cell type and organ-dependent regulatory mechanisms (Vischioni et al., 2006). Moreover, Yan and colleagues (2004) demonstrated a tumor stage-dependent increase of both XIAP mRNA and protein expression in renal cell carcinoma (Yan et al., 2004). At a protein level, XIAP activity may also be negatively regulated by the interaction with specific endogenous inhibitors, i.e. DIABLO (diablo IAP-binding mitochondrial protein), HTRA2 and XAF1 (XIAP-associated factor-1) (Srinivasula & Ashwell., 2008; Desplanques et al., 2009; Ye et al., 2019; Abbas & Larisch, 2020), or stabilized by other IAPs and proteins to enhance its activity (Dohi et al., 2004; Rajalingam et al., 2006). XIAP also forms a complex with SIVA1 and NR2C2 (TAK1), which inhibits XIAP/TAK1/ TAB1 -mediated NFκB activation, activates JNK activity and modulates apoptosis responses (Resch et al., 2009). | ||||||||||||||||||||||||||||||||||||||||
| Localisation | Subcellular localization of XIAP is heterogenous, but it is predominantly cytoplasmic, being found in the nucleus also in the membrane. Immunofluorescence of transfected HeLa cells indicated that XIAP localized to the cytoplasm, being more prominent in the peri-nuclear region. The study also aimed to evaluate if co-expression of XIAP and XAF1 could alter its localization and concluded that the expression of XAF1 induced redistribution of XIAP from cytoplasm to nucleus (Liston et al., 2001). Germ and Sertoli cells displayed XIAP in both cytoplasm and nucleoli (Vischioni et al., 2006). Fluorescence staining of hNOKs (human normal oral keratinocytes) revealed XIAP to be localized mainly in the cytoplasm and perinuclear areas, whereas in Tca8113 cell line (squamous cell carcinoma of the human tongue) high levels of this IAP were found both in the cytoplasm and the nucleus (Gao et al., 2006). In gastric cancer tissue samples, XIAP expression was detected exclusively in the cytoplasm (Dizdar et al., 2017). XIAP displayed different patterns of localization in pancreas: acinar exocrine cells showed stronger staining in a granular supranuclear position (alike in glands of the small intestine and in the bronchial epithelium); while ductal cells presented XIAP diffused in the cytoplasm (Vischioni et al., 2006). A granular pattern in the cytoplasm had already been described in NSCLC cells, mainly in adenocarcinoma sections (Ferreira et al., 2001a; Ferreira et al., 2001b). XIAP membrane localization was described in endometrial glands, more prominently in brush border or basolateral type. The interaction of XIAP with bone morphogenetic protein (BMP) type I receptors via its RING-finger domain also suggests a possible localization in the plasma membrane (Yamaguchi et al., 1999; Vischioni et al., 2006). | ||||||||||||||||||||||||||||||||||||||||
| Function | XIAP function has been widely described, presenting involvement in multiple cellular signaling pathways, including cell death, immunity, inflammation, cell cycle, and cell migration (Vucic, 2018). This multiplicity of activities is partially due to the distinct domains present in XIAP. Still, the main function of this protein is the inhibition of the apoptosis cascade due to its binding to the initiator CASP9 (caspase-9), and the effector CASP3 and CASP7 (caspases 3 and 7), via its BIR3 and BIR2 domains, respectively, as demonstrated in figure 2 (Obexer and Ausserlechner, 2014). Another important mechanism for caspase inhibition by XIAP involves the E3 ligase activity of the RING domain, which is correlated with ubiquitination of XIAP-bound caspases. Thus, it can be concluded that XIAP interferes with extrinsic as well as intrinsic death pathways (Pistritto et al., 2016). Such ubiquitination activity may be associated with XIAP itself, XIAP-interacting proteins involved in apoptosis, and other different targets involved in apoptosis (Galban and Duckett, 2010). XIAP has also been correlated to suppression of autophagy, once depletion of this IAP resulted in increased expression of SQSTM1 (p62), a feature induced, in fact, by prevention of the ubiquitin-proteasomal degradation of SQSTM1 mediated by E3 ligase activity of XIAP (Huang et al., 2019). Another study evidenced that XIAP also localizes to the mitochondria, deregulating its functions, especially concerning cytochrome c release, suggesting that XIAP may enhance mitochondrial membrane permeabilization and control cytochrome c release (Chaudhary et al., 2016). Furthermore, the tumor suppressor protein SEPTIN4, expressed in the outer mitochondrial membrane, promotes cell death through the antagonism of XIAP, leading XIAP to execute ubiquitination and degradation of BCL2 and, consequently, apoptosis (Edison et al., 2017), reinforcing the role the mitochondria plays in XIAP homeostasis. Recently, it was demonstrated that XIAP physically interacts with HSP70 and, interestingly, that the use of HSP70 inhibitors promotes down-regulation of XIAP in both cancer cell lines and xenograft tumors (Cesa et al., 2017) . In normal development, XIAP levels and function were studied using XIAP-deficient mice. Histopathological analysis revealed no differences compared to wild-type mice and, moreover, no defects in induction of caspase-dependent or -independent apoptosis were observed. However, other IAPs proteins were found to be upregulated, including BIRC2 and BIRC3, which suggests the existence of a compensatory mechanism (Harlin et al., 2001). Still, in cancer, high XIAP levels have been correlated with a poor prognosis (Cossu et al., 2019). | ||||||||||||||||||||||||||||||||||||||||
 | |||||||||||||||||||||||||||||||||||||||||
| Figure 2. XIAP (BIRC4) is a multi functional protein. XIAP is involved in multiple cellular signaling pathways and cellular processes, including cell death, inflammation, cell cycle, and cell migration. The multifunctionality of XIAP is possible due to the different domains presented. The main function attributed to XIAP is its antiapoptotic activity, acting on intrinsic and extrinsic apoptotic pathways. XIAP binds and inhibits CASP9 (caspase 9) and its effectors CASP3 and CASP7 (caspase 3 and caspase 7). XIAP also acts on caspase inhibition by ubiquitination. XIAP has also a role in the suppression of autophagy, once its depletion resulted in increased expression of SQSTM1 (p62), a feature induced, in fact, by prevention of the ubiquitin- proteasomal degradation of SQSTM1 mediated by E3 ligase activity of XIAP. XIAP has been linked to cytochrome C release, suggesting that XIAP may enhance mitochondrial membrane permeabilization. It was demonstrated that XIAP physically interacts with HSP70 and, interestingly, that the use of HSP70 inhibitors promotes down-regulation of XIAP. In addition, XIAP regulates TAB1/NR2C2/NFKB1 axis modulating apoptosis. | |||||||||||||||||||||||||||||||||||||||||
| Homology | XIAP has high homology among different species (Table 1). Table 1. Comparative identity of human XIAP with other species
(Source: http://www.ncbi.nlm.nih.gov/homologene) |
| Mutations |
| Somatic | Recurrent mutations in the XIAP gene are rare. Among the 47,186 samples reported in COSMIC (Catalogue of Somatic Mutations in Cancer; http://cancer.sanger.ac.uk/cancergenome/projects/cosmic), 182 mutations were reported in XIAP (138 missense substitutions, 23 synonymous substitutions, 14 nonsense substitutions, 3 frameshift deletions and 2 frameshift insertions). In cBioPortal (http://www.cbioportal.org), among the 42,119 (159 studies) cancer samples accessed, only 0.5% presented XIAP mutations (corresponding to 195 mutations, of which 171 are missense substitutions, 22 truncated genes and 2 other mutation). When mutations, amplifications, deep deletions and multiple alterations were considered, the total of cancer samples bearing any type of genetic alteration in XIAP was 351 (0.8%). |
| Implicated in |
| Entity | Bladder cancer |
| Note | XIAP, BIRC7, and BIRC5 were found to be simultaneously expressed in bladder cancer cells, with synergistic effects on cell growth and apoptosis. Knockdown assays targeting these three genes synergistically inhibited the proliferation and in vitro transformation ability, while also promoting apoptosis (Yang et al., 2010). XIAP levels can be considered a biomarker of malignancy for bladder carcinoma, once it was found up-regulated in urine samples from bladder carcinoma patients compared to samples of patients with non-malignant bladder diseases (Srivastava et al., 2015). In urinary cancer, XIAP expression was shown to play a key role in the maintenance of tumor phenotype mediating multiple pathways: XIAP overexpression promoted bladder cancer invasion in vitro and lung metastasis in vivo through activation of the MAPK1 / NCL/ ARHGDIB axis (Yu et al., 2018). Also, its BIR domain regulated the EGFR translation by suppressing MIR200A expression and promoting cancer development and progression (Huang et al., 2017). The RING domain of XIAP also contributed to malignant transformation in bladder cancer, once it inhibited the expression of TP63, a known tumor suppressor, critical for the transformation of normal urothelial cells (Jin et al., 2016). In T24 and 5637 cell lines, XIAP overexpression was reverted by embelin treatment that promoted a dose-dependent cell death mediated by the PI3K/AKT pathway (Fu et al., 2016). The use of DIABLO IAP-binding mitochondrial protein mimetics (UMUC-6, UMUC-12, and UMUC-18) in combination with typical chemotherapy drugs like cisplatin and gemcitabine promoted increased apoptosis, decreased microvessel density and decreased cellular proliferation that was shown to be related to the inhibition of IAPs, including XIAP (Lee et al., 2013). |
| Entity | Brain cancer |
| Note | New potential therapeutic targets in glioblastomas were investigated by analyzing the expression and function of eight proteins that are known to play a role in cell survival and therapy resistance. The analysis of 50 samples from glioblastoma patients by immunohistochemistry revealed high expression of XIAP and ABCG2 (also known as BCRP, a member of the ABC transporters that use ATP to efflux endogenous small molecules and exogenous cytotoxic drugs) at the protein level were related to poor survival (Emery et al., 2017). Another study evaluated the expression of anti and pro-apoptotic genes in 30 samples of glioblastoma patients by real-time PCR, which found higher levels of XIAP and BCL2 in glioblastoma samples compared to 10 samples from white matter control (Tirapelli et al., 2017) . Additionally, higher XIAP mRNA levels were found on CD133+ compared to CD133- adult glioblastoma primary cultured cells (LIU et al., 2006). Higher levels of XIAP were also seen in DAOY and D283MED cells compared to normal human astrocytes and immortalized fibroblasts. Moreover, expression of XIAP inversely correlated with that of CDKN1A (p21), suggesting IAPs may be involved in cell cycle control by CDKN1A suppression (CHEN et al., 2018). Treatment with IAP inhibitors LCL161 or LBW242 alone or in combination with conventional chemotherapeutic agents, i.e. vincristine or cisplatin, as well as RNAi-mediated knockdown of XIAP, arrested the cell cycle at the G2/M phase through downregulation of CCNB1 - CDK1 and CCNA2 -CDK1/ CDK2 complexes in DAOY and D283MED cells (Chen et al., 2018). These IAP inhibitors combined with chemotherapy also enhanced the antiproliferative effect on MB cell line through autophagy induction and CASP3/CASP7-activated apoptosis (Chen et al., 2016). Treatment with IAP inhibitors LCL161 or LBW242 alone or in combination with conventional chemotherapeutic agents, i.e. vincristine or cisplatin, as well as RNAi-mediated knockdown of XIAP, arrested the cell cycle at the G2/M phase through downregulation of CCNB1-CDK1 and CCNA2-CDK1/CDK2 complexes in DAOY and D283MED cells (Chen et al., 2018). These IAP inhibitors combined with chemotherapy also enhanced the antiproliferative effect on MB cell line through autophagy induction and CASP3/CASP7-activated apoptosis (Chen et al., 2016). In U87MG glioblastoma cells, treatment with isolinderalactone, a sesquiterpene found in the roots of L. aggregata, resulted in a significant dose-dependent reduction of XIAP, BIRC5 and BCL2 levels, and apoptosis induction (Hwang et al., 2019). Crude extracts of medicinal herbs (crude alkaloid extract of R. stricta and crude flavonoid extract of Z. officinale) decreased mRNA expression levels of XIAP, BIRC5 and CCND1, while expression of CDNK1A and PMAIP1 were upregulated in U251MG cell line (Elkady et al., 2014). XIAP and MYC expression were significantly decreased in 51A and SU-2 cell lines after treatment with HDAC6 inhibitor, resulting in decreased CHEK1 activity through proteasomal degradation, leading to radio-sensitivity and reduced DNA damage repair capacity of glioma stem cells, a group of 'stem-like' cells hardly to be completely removed, thus conferring resistance to radio and chemotherapy in glioblastoma (Yang et al, 2017). |
| Entity | Breast cancer |
| Note | IAPs were shown to be overexpressed in various numbers of cancers, including breast cancer and were associated with a poor prognosis and drug resistance (Moraes et al., 2015, Huang et al., 2018), making them an interesting target for therapy. In immunohistochemical experiments, it was shown that XIAP positively stained the majority of breast cancer cells with moderate or strong intensity (Zohny; Zamzami; El-Shinawi, 2018). In another study, it was found that in one third of breast cancer patients presented XIAP overexpression, which was associated with a reduced overall survival (Hussain et al., 2017). In a study with inflammatory breast cancer (IBC) was noticed that XIAP was also overexpressed in IBC patient tumors and high-grade breast cancers, corroborating XIAP overexpression in breast cancer (Evans et al., 2018). Additionally, high XIAP expression was associated with reduced CASP3 activation and apoptosis rates in breast cancer tumors compared to benign breast lesions. In immunoreactivity studies using breast cancer samples, high XIAP expression was found, but it did not correlate with age, tumor size, grade, status of lymph node, expression of ESR1 (estrogen receptor) and PGR (progesterone receptor). In addition, XIAP expression was found in 80% of patients with triple-negative invasive ductal breast cancer and it was related with primary tumor size and reduced disease-free survival and overall survival (Zohny; Zamzami; El-Shinawi, 2018). |
| Entity | Cervical carcinoma |
| Note | Immunohistochemistry analysis of 15 cases of normal cervical tissues, 69 cases of cervical intraepithelial neoplasia (CIN) and 76 cases of cervical carcinoma revealed increased expression of XIAP in tumor than normal tissues, inversely associated with diablo (Smac) expression. In the same study, XIAP expression was associated with pelvic lymph node metastasis (Jin et al., 2017). A semi quantitative RT-PCR analysis of 6 normal and 41 cancer tissues, including 8 stage I cases, 16 stage II and 17 stage III revealed no differences in the expression of XIAP between normal and tumor samples. However, an unexpected positive association between low levels of XIAP and disease relapse was observed, and an inverse relation between XIAP expression and tumor aggressiveness (Espinosa et al., 2006). The crude extract of the Chinese herb Antrodia camphorata induced apoptosis in HeLa and C-33A cells, showing a decrease in the expression of XIAP among other anti-apoptotic proteins (Yang et al., 2013). Xanthohumol, a prenylated chalcone isolated from Humulus lupus, also downregulated expression of anti-apoptotic proteins such as XIAP in Ca Ski cervical cancer cell line, inhibiting proliferation (Yong et al., 2015). |
| Entity | Colorectal cancer |
| Note | XIAP mRNA expression was shown to be upregulated in a study comparing 100 cancer to 100 normal tissues from patients with sporadic colorectal cancer by real time PCR, of which half were KRAS wild-type and the other half KRAS mutant (Devetzi et al., 2016). XIAP was also shown to be upregulated while pro-apoptotic BAX and BID were downregulated in HT-29 cells resistant to 5-FU compared to wild type (Manoochehri et al., 2014). In contrast, the expression of XIAP and other IAPs, except BIRC3, did not show significant differences in the normal mucosa of patients with advanced colorectal adenoma (Choi et al., 2017). The diablo IAP-binding mitochondrial protein mimetic BV6, reduced cellular levels of XIAP, re-sensitizing BAX-deficient HCT-116, wildtype HCT-116, HCT-8 and DLD1 cells grown under hypoxic conditions to TNFSF10 and/or FASLG (CD95L) -induced cell death (Knoll et al., 2016). In addition, XIAP-deficient HCT-116 cells showed significant less TRAIL resistance under hypoxia compared to HCT-116 wild type cells (Knoll et a., 2016). BV6 also substantially increased 3D radiation response of HCT-15, HT-29 and SW480 cells upon BIRC2 and XIAP degradation, resulting in enhanced irradiation-induced apoptosis and DNA double-strand break repair hampering (Hehlgans et al., 2015). Agreeing with this, combinatorial treatments with TNFSF10 and Smac mimetics or XIAP-targeting drugs were reported to overcome hypoxia-induced TNFSF10 resistance, demonstrating that a reasonable alternative was to target XIAP as well as TNFSF10 in order to obtain stronger responses (Knoll et al., 2016). Upregulation of XIAP might also be responsible for the acquired resistance to oxaliplatin, as established oxaliplatin-resistant SW480 and HT29 cells were shown to express significantly higher levels of XIAP and lower levels of MIR122 compared to wild types. A recovery of miR-122 expression was able to sensitize these colorectal cancer cells to oxaliplatin-mediated apoptosis through inhibition of XIAP expression. Thus, XIAP may offer a good strategy for reducing oxaliplatin resistance in colorectal cancer (Hua et al., 2018). Transcriptomic analysis revealed that propionibacterial supernatant or its metabolites (propionate and acetate) increased pro-apoptotic gene expression (TNFSF10) and reduced anti-apoptotic gene expression of CFLAR and XIAP when administered in combination with TNFSF10 in HT-29 cells (Cousin et al., 2016). In HT29 cells, mithramycin A selectively downregulated XIAP through inhibition of SP1 binding to its promoter. Suppression of XIAP transcription, by siRNA, enhanced TNFSF10-induced apoptosis even though its overexpression significantly attenuated apoptosis induced by MithA plus TNFSF10, indicating a critical role for XIAP in the recovery of TRAIL sensitivity in various cancer cells (Lee et al., 2006). Impaired CASP3 maturation by XIAP was also identified as one of the underlying mechanisms relating XIAP to TNFSF10 resistance in HCT-116 PIK3CA -mutant cells, as TNFSF10 sensitivity was efficiently restored after XIAP or proteasome inhibition, indicating that targeting XIAP or the proteasome in cells with PIK3CA mutations, which are found in 10-20% of colorectal tumors, may represent a good therapeutic strategy concerning TNFSF10 (Ehrenschwender et al., 2014). COLO 205 and HCT-116 cells transfected with shRNA targeting AKAP4 (A-kinase anchor protein 4) resulted in XIAP downregulation among other anti-apoptotic molecules, while pro-apoptotic molecules were upregulated (Jagadish et al., 2015). TGFB1 / PRKACB (PKA) / PP2A signaling deactivated AKT phosphorylation leading to downregulation of XIAP and BIRC5 in FET cell line (Chowdhury et al., 2011 A; Chowdhury et al., 2011 B). Bufalin, a steroid-related molecule, in association with 5-fluorouracil reduced the expression of XIAP and other IAPs, while elevated the expression of pro-apoptotic proteins (Dai et al., 2018). Moreover, MK-2206, an allosteric kinase inhibitor of AKT, dephosphorylated EZR (ezrin) at the T567 site and led to disruption of AKT-EZR-XIAP cell survival signaling (Agarwal et al., 2014). Phosphorylation of EZR at the T567 site was regulated by the IGF1R signaling pathway, and such activation enhanced cell survival in colorectal cancer cells by modulating XIAP and BIRC5 in both orthotopically implanted GEO tumors, as well as, human patient specimens (Leiphrakpam et al., 2014). SATB2 (special AT-rich binding protein-2) overexpression resulted in upregulation of XIAP and CCND1 in CRL-1831 cells (Yu et al., 2017). Silencing PIK3CA (PI3K p110α), by siRNA, also resulted in alterations in the expression of XIAP in KRAS/PIK3CA-mutant HCT-116 (Fernandes et al., 2016). Placet et al. (2018) suggested that P2RY6 receptor could be targeted to block XIAP activity in colorectal cancer. P2RY6 stimulation with its selective agonist MRS2693 induced XIAP phosphorylation on Ser87 residue, concomitant to phosphorylation of AKT Thr3008 residue, and it was correlated to XIAP increase and maintenance over time. These findings suggested that P2Y6R antagonists could be used to block XIAP activity and enhance the therapeutic effect of drugs such as 5-fluorouracil (Placet et al., 2018). |
| Entity | Esophageal cancer |
| Note | Immunohistochemistry analysis of 120 esophageal squamous cell carcinoma (ESCC) and 90 esophageal adenocarcinoma (EAC) tissues with their corresponding normal mucosa samples revealed high expression levels of XIAP in tumor tissues. The same study identified XIAP as an independent negative prognostic marker in ESCC (Dizdar et al., 2018). Another study using immunohistochemistry of 78 ESCC patients treated with radiotherapy after surgery revealed increased XIAP expression and it was correlated with tumor differentiation and TNM stage (Zhou et al., 2013). Schiffmann and colleagues also reported XIAP expression might serve as a tool to improve outcome prediction and identify high-risk patients, whom may be a candidate for a more aggressive therapy strategy (Schiffmann et al., 2019). Additionally, 170 ESCC patients and 191 healthy people were genotyped and related polymorphisms rs8371 and rs9856 with susceptibility to ESCC, and rs8371 polymorphism might serve as an indicator improved clinical efficacy and prognosis (Peng et al., 2017) . Treatment of five ESCC cell lines with TNF combined to cycloheximide (CHX) induced significant apoptosis and decreased expression of XIAP and BIRC2. This effect was not seen when cells were treated with either TNF or CHX alone, but XIAP or BIRC2 siRNA transfected cells underwent apoptosis when TNF was administered alone, a result that was further increased by double knockdown, suggesting XIAP along with BIRC2 might play an essential role in apoptosis-resistance of ESCC cells (Hikami et al., 2017). Esophageal cancer cells treated with siRNA targeting XIAP in combination to radiotherapy presented decreased cell survival rate and colony forming efficiency. Besides, nude mice treated with siRNA had a decrease in tumor weight and volume compared to control group, indicating that XIAP gene silencing could be an allied in radiotherapy strategies for esophageal cancer (Wen et al., 2017). Treatment with siRNA targeting XAIP also enhanced chemosensitivity of ESCC cells, as seen in a study that combined this strategy with paclitaxel, cisplatin, 5-fluorouracil and etoposide (Zhang et al., 2007). |
| Entity | Gastric cancer |
| Note | An analysis for expression of IAPs in over 1,100 surgically resected gastric cancer (GC) tissue specimens revealed XIAP was present in 20% of the cases, whereas XIAP inhibitors, such as XAF1 and diablo IAP-binding mitochondrial protein, were seen in 76.6% and 13.9% of cases respectively. XIAP expression was strongly related to advanced stage. In the same study, high expression of XIAP was also related to decreased patient survival rates, indicating this as an independent prognostic factor for poor survival outcomes (Kim et al., 2011). Another study considering 144 patients also found that XIAP expression levels were significantly related to tumor size, serosal invasion and lymph node metastasis. The authors further demonstrated that XIAP expression was significantly elevated in HGC-27 and MGC803 gastric cancer cell lines compared to GES-1 normal gastric epithelial cells (Li et al., 2018). In addition, among other eight proteins, XIAP was seen to be upregulated in AFP (alpha-fetoprotein) producing gastric adenocarcinoma, and its overexpression was correlated to poor relapse-free survival and overall survival, but not in the AFP non-producing patients (He et al., 2016). XIAP and BIRC5 levels were evaluated in 201 patients who underwent total or subtotal gastrectomy and extended (D2) lymphadenectomy. High levels of both IAPs were seen in gastric cancer tissue specimens when compared with normal mucosa and were correlated with an intestinal-type and well-differentiated gastric cancer, as also to low UICC stages. High levels of XIAP was detected in lymph node metastasis compared to corresponding primary tumors, which supports the hypothesis that it also plays an important role in metastatic tumors. XIAP overexpression was identified as an independent negative prognostic marker in diffuse and mixed type of gastric cancer. Tissue microarray revealed XIAP was present only in the cytoplasm, whereas BIRC5 was found in both the nucleus and the cytoplasm. The authors also identified a positive correlation between cytoplasmic BIRC5 and XIAP expression (Dizdar et al., 2017). XIAP was downregulated after treatment with cycloheximide (CHX) and the effect was enhanced when combined CHX to TNF, resulting in induced apoptosis that may occur by accelerated proteasome-mediated degradation of XIAP and other IAP family members in addition to inhibition of NFKB1-dependent synthesis of anti-apoptotic molecules (Kitagawa et al., 2015). Treatment with L-asparaginase in human gastric adenocarcinoma cells (AGS) significantly down-regulated anti-apoptotic genes i.e. XIAP, BID, MCL1, and death receptors TNF and TRADD, while pro-apoptosis genes i.e. BAK1, BAX, BIK, APAF1, CASP3, CASP7, and CASP9 were upregulated. Further analysis confirmed intrinsic apoptosis pathway activation (Sindhu et al., 2018). Treatment with H72, a synthetic brominated chalcone derivative, reduced protein levels of XIAP, BCL2L1, and BIRC5, while increased levels of BCL2L11 BIM, TNFRSF10A (DR4), and TNFRSF10B (DR5), with no changes in BAX levels in MGC803 cells (Zhang et al., 2016). Furthermore, scutellarein, a flavone glycoside obtained by hydrolysis of scutellarin found in herbs from Scutellaria genus, induced apoptosis and inhibited cell proliferation via down regulation of MDM2, which activates the tumor suppressor protein TP53, leading to down regulation of XIAP, BIRC2 and BIRC3 in a dose-dependent manner in AGS and SNU-484 gastric cancer cells (Gowda Saralamma et al., 2017). CDK7 selective inhibition by BS-181, a pyrimidine-derived compound, induced apoptosis due to a significant decrease in XIAP and CCND1 expression in BGC823 cells (Wang et al., 2016). A double knockdown of both XIAP and BIRC5 expression by siRNA resulted in a notable increase in apoptosis rates and suppression of cell proliferation compared to cells submitted to a single knockdown of either BIRC5 or XIAP (Li et al., 2018). XIAP levels were inversely correlated to expression of MIR509-3p in tissue specimens collected from patients with gastric cancer, which was a clinically significant miRNA detected in higher abundancy in patients with favorable survival states, both in The Cancer Genome Atlas and in an independent cohort (Pan et al., 2016). Paired tissues revealed significant downregulation of miR-509-3p in tumor tissues, and such downregulation was strongly correlated to poor outcomes (Sun et al., 2017). |
| Entity | Head and neck squamous cell carcinoma |
| Note | Immunohistochemistry assays revealed XIAP expression in 40 of out 59 sections from routinely processed specimens of head and neck squamous cell carcinoma (HNSCC), in which staining varied from weak or focal to strong or diffuse (Nagi et al., 2007). XIAP expression was found in 17 out of 60 samples accessed, which was associated with cisplatin resistance and poor clinical outcome in advanced HNSCC patients. Chemotherapy with cisplatin induced XIAP expression. In HNSCC cells, cisplatin sensibility was significantly increased after inhibition of XIAP by siRNA. Along with alcohol consumption and lymph node metastasis, XIAP was found to be an independent prognostic marker of advanced HNSCC patients (Yang et al., 2012). Moreover, Yang and other colleagues (2018) reported that patients with HNSCC co-expressing high levels of XIAP and BIRC2 had shorter overall and disease-free survival compared to patients expressing low levels of both IAPs, indicating a synergistic effect of these proteins on prognosis (Yang et al., 2018). Depletion of XIAP, by shRNA, significantly enhanced cell death after treatment with TNFSF10 combined to bortezomib in UPCI:SCC089 and UPCI:SCC090 cell lines (Bullenkamp et al., 2014). |
| Entity | Kidney cancer |
| Note | XIAP expression was upregulated and associated with poor prognosis in kidney cancer patients (Mizutani et al., 2007; Bilimet al., 2008). It was also shown that the decrease in the expression of XIAP by antisense oligonucleotide enhanced sensibility of renal cell carcinoma cells to FAS/ TNFSF10-mediated cytotoxicity (MizutaniI et al., 2007). In renal cell carcinoma, XIAP expression increased from early (pT1) to advanced tumor stages (pT3), similarly to dedifferentiation stages and tumor aggressiveness (Yan et al., 2004; Ramp et al., 2004). Among the different histological renal cell carcinomas, it was observed that the clear cell type, that has a poor diagnosis, had a higher XIAP expression than the papillary (Yan et al., 2004). In addition, XIAP expression was found in 137 of 145 (95%) of the investigated clear cell renal cell carcinoma, a tumor of the kidney that accounts 70% of all renal cell carcinoma. |
| Entity | Leukemia |
| Note | Leukemia cells appear to have anti-apoptotic proteins in order to survive under hostile conditions (Walsby et al., 2013), and studies have shown that these molecules may be useful as prognostic markers (Tamm, 2004). XIAP was frequently overexpressed in leukemia cells, serving as regulators in the cell survival (Hu et al., 2014). In a panel made purposely for the study of the relation of IAPs and leukemia containing 60 human tumor cell lines showed, among acute myeloid leukemia (AML) blasts derived from newly diagnosed patients, that patients with low levels of XIAP had a longer survival rate and were inclined to a longer median remission duration. This finding implied that XIAP has a potential prognostic value in AML (Tamm et al., 2000). In adult acute myeloid leukemia (AML), XIAP expression was lower in AML cells with granulocytic differentiation when compared to myelomonocytic-differentiated cells, which suggests that XIAP plays a role in normal monocytic and malignant differentiation. Supporting this finding, downregulation of XIAP blocks monocytic differentiation induced by bryostatin 1 in leukemia cells (Tamm, 2004). One of the most well-known XIAP inhibitor is embelin, a cell-permeable and small molecule that inhibits XIAP through DIABLO IAP-binding mitochondrial protein. Embelin was shown to promote downregulation of XIAP and release of CASP9, which normally initiates caspase cascades and leads to apoptosis. Furthermore, embelin induces apoptosis in leukemia cell line HL60 by XIAP downregulation (Hu et al., 2014). Additionally, it was demonstrated that low-toxicity embelin sensitization of HL60 cells to TNFSF10 -induced apoptosis was not intimately related to XIAP inhibition, showing that low-toxicity embelin alone or jointly with TNFSF10 did not change the expression of XIAP (Hu et al., 2014). There are other molecules proposed as XIAP inhibitors, including CDKI-73, which also inhibited MCL1, BCL2, CCND1 and CCND2 (Walsby et al., 2013), and nilotinib, which was shown to inhibit the expression of XIAP in two MDM2-overexpressing cell lines, suggesting that nilotinib-mediated XIAP inhibition was dependent of MDM2, since this was not observed for MDM2-negative cell line (Zhang et al., 2014). In leukemia cells, the co-treatment with SAHA and S116836 repressed anti-apoptotic proteins, including XIAP (Bu et al., 2014). Natural products were also studied regarding its effects on XIAP inhibition, for instance, AVO (an essential oil from Artemisia vulgaris L) decreased the expression of XIAP leading to inhibition of the activation of caspases 9 and 3 in HL60 leukemia cells (Saleh et al., 2014). |
| Entity | Liver cancer |
| Note | In hepatocellular carcinoma patients, XIAP expression was associated with poor overall survival and, in cell lines, was shown to play an important role in modulating cell apoptosis and cell cycle progression through regulation of CDK4, CDK6 and CCND1 via NFKB1 and PTEN pathways (Che et al., 2012). Treatment of hepatocellular carcinoma cells with embelin resulted in increased apoptosis and decreased cell proliferation via an arrest at the G1 phase (Che et al., 2012). In contrast, it was observed that apoptosis resistance may be related to a significantly lower expression of XAF1, but not XIAP in poorly differentiated hepatocellular carcinoma tissues (Sakemi et al., 2007). Zhu and colleagues reported lower levels of XAF1 expression in SMMC-7721, HepG2 and BEL-7404 cell lines, as well as in liver cancer tissues compared to their paired non-cancer hepatic tissues. Adenovirus-mediated XAF1 expression (Ad5/F35-XAF1) significantly inhibited cell proliferation and induced apoptosis, while significantly suppressed xenograft tumor growth of hepatocarcinoma cells (Zhu et al., 2014). XIAP was also associated with therapeutic resistance to the histone deacetylase (HDAC) inhibitor JNJ-2648158, which induced the transcription of XIAP through AP1 expression activation, conferring resistance to apoptosis (Wang et al., 2018). Moreover, Winkler and colleagues (2014) reported XIAP to play an important role in the pro-survival function of the exportin cellular apoptosis susceptibility (CAS) in hepatocellular carcinoma models (Winkler et al., 2014). Cisplatin treatment downregulated XIAP expression, while XIAP knockdown by siRNA enhanced the pro-apoptotic effects of cisplatin in LM3 cell line (Shang et al., 2018). A fraction of the natural extract derived from Artemisia capillaris obtained in ethyl acetate displayed growth and proliferation inhibition, induced apoptosis, increased levels of cleaved caspase-3 and decreased XIAP, BIRC5, and MCL1 expression in HepG2 and Huh7 cell lines (Yan et al., 2018). |
| Entity | Lung cancer |
| Note | In a study of the protein signature for non-small cell lung cancer (NSCLC) prognosis, XIAP was differentially expressed between NSCLC and benign lung tumor, indicating that XIAP is a potential biomarker for malignancy in lung tumors. Along with other proteins, XIAP was also correlated to invasion and lymph node metastasis, as well as squamous differentiation (Liu et al., 2014). In agreement, Huang and coworkers (2015), reported high levels of XIAP in lung cancer tissues compared to adjacent tissues samples (Huang et al., 2015). In contrast, Moravcikova et al. (2014) indicated that XIAP was not an effective suppressor of the apoptosome apparatus activity in NSCLC cells, suggesting that apoptosome-generated caspase-3 activity can overcome the potential caspase inhibitory effect of XIAP. Baykara and colleagues (2013) also investigated the relation of XIAP with clinical parameters in NSCLC. XIAP levels were determined by ELISA in samples from 34 NSCLC patients and 44 healthy individuals, but no correlation between serum XIAP levels and response to chemotherapy, progression free-survival or overall survival were found (Baykara et al., 2013). Kang and colleagues (2008) performed an evaluation of the association between XIAP polymorphisms and the risk for lung cancer. The authors identified 12 SNPs and selected 4 of them for large-scale genotyping based on their frequencies and haplotype tagging status, but no evidence of relation of XIAP polymorphisms with the risk of lung cancer was observed (Kang et al., 2008). XIAP-mediated ERK activation upregulated NCL (nucleolin) expression, which was able to stabilize ARHGDIB mRNA and mediate lung metastatic (Yu et al., 2018). In lung cancer cells, XIAP inhibited mature SMAC-induced apoptosis by degrading it through ubiquitination (Qin et al., 2016). Combined treatment of lambetianic acid (LA) and TRAIL displayed significantly decreased antiapoptotic proteins such as XIAP, while also disrupting its binding with CASP3 or NFKB1, enhancing TNFSF10-induced apoptosis (Ahn et al., 2018). |
| Entity | Lymphoma |
| Note | Mantle cell lymphoma, a poor prognosis and metastatic-related non-Hodgkin B-cell malignancy, presented overexpression of IAPs, including XIAP. In mantle lymphoma cells, B-PAC-1, a procaspase activating compound, induced apoptosis by the sequester of Zn bound to procaspase- 3, (Sarkar et al., 2015) or when analyzing the anti-tumor properties of puerarin (Gan Yin, 2014). Similar to findings in mantle cell lymphoma, XIAP protein was upregulated in other lymphomas, such as Burkitt's lymphoma, a highly aggressive type of non- Hodgkin B-cell lymphoma (Aaqarni et al., 2018). In lymphoma cells, antitumor properties of indole-3-carbinol was related to XIAP downregulation (Perez-Chacon; Rios; Zapata, 2014). In B-cell lymphomas, XIAP was overexpressed and associated with chemoresistance and shorter survival outcomes. Double knockdown of XIAP and USP9X delayed lymphoma development, corroborating XIAP as a target in lymphoma (Engel et al., 2016). |
| Entity | Medulloblastoma |
| Note | XIAP was shown to be upregulated in medulloblastoma cells, while XIAP inhibitors reduced cell proliferation and induced cell death. In fact, this effect was also seen in the subpopulation CD133+ stem-like medulloblastoma cells, for which XIAP expression displayed even higher levels. In agreement, XIAP expression in cytoplasm was found in 75% of the medulloblastoma tissues compared with no expression in normal brain tissues (Chen et al., 2016). Inhibition of XIAP, BIRC2 or BIRC3 combined with conventional chemotherapy resulted in cell cycle arrest at G2/M phase in medulloblastoma cells (Chen et al., 2018). These findings indicated that XIAP was a potential diagnostic marker and therapeutic target in medulloblastoma. |
| Entity | Melanoma |
| Note | In melanoma, the machinery behind the high resistance may be related to overexpression of proteins of the IAP family, including XIAP (Hiscutt et al., 2010; Mohana-Kumaran et al., 2014). XIAP was associated with cell growth, tumorigenesis, metastasis as well as progression in melanoma cells (Li; Ke; Wang, 2012), and it was shown to be overexpressed in primary cutaneous and metastatic melanoma tissues (Hiscutt et al., 2010). In a study where XIAP expression was investigated in 55 samples of clinical patients and where samples consisted mainly of superficial spreading melanoma, XIAP expression was found to be higher in late stage primary cutaneous melanoma. There was also a significant difference on the percentage of cells positive for XIAP in sample obtained from patients that were stage II melanoma and benign nevi. When analyzing the range of thickness of primary tumors, the increase on XIAP expression was associated with a greater Breslow thickness (Tian; Lee, 2010). In another study, XIAP expression was also higher on thick cutaneous melanoma than when compared to thin ones (Emanuel et al., 2008). |
| Entity | Multiple myeloma |
| Note | Multiple myeloma cells exhibited high levels of XIAP protein, which was associated with myeloma-related growth factors. In the same study, XIAP silencing by RNAi increased drug sensitivity in in vitro assays and reduced in vivo tumor formation. Multiple myeloma cells also expressed XAF1, which antagonizes the caspase inhibitor function of XIAP (Desplanques et al., 2009). |
| Entity | Neuroblastoma |
| Note | In neuroblastoma patients, XIAP was found in 18 among the 19 cases analyzed, and the level of XIAP was higher within patients that had no bone marrow metastasis. XIAP expression was also higher in patients with favorable histology regardless of bone marrow status. XIAP expression had no significant difference on tumors with undifferentiated/poorly differentiated histology compared to differentiating subtypes (Osman et al., 2013). Post transcriptional and transcriptional mechanisms were related with high XIAP expression, which had been targeted by diablo IAP-binding mitochondrial protein mimetic LBW242 in neuroblastoma. Using microarray analysis, XIAP mRNA was associated with risk of relapse in a cohort of 101 neuroblastoma patients (Eschenburg et al., 2012). In paired neuroblastoma cell lines obtained from a primary tumor of a female patient pre- and post-chemotherapy (CHLA-15 and CHLA-20), XIAP was highly expressed in CHLA-20 cells, which had undergone an intensive treatment with cyclophosphamide, doxorubicin, cisplatin and teniposide (Frommann et al., 2018). |
| Entity | Oral cancer |
| Note | Using tissue microarray, high XIAP expression was associated with a significant reduction in overall survival in a cohort of 193 squamous cell carcinomas (Frohwitter et al., 2017). HSC-3 cells treated with ursodeoxycholic acid (UDCA) and Ca9-22 cells treated with furano-1,2-naphthoquino (FNQ) and PP2 (a Src-specific inhibitor) presented XIAP downregulation (Lin et al., 2014; Pang et al., 2015). |
| Entity | Osteosarcoma |
| Note | Qu and colleagues reported that XIAP mRNA and protein levels were increased in osteosarcoma compared to adjacent non-tumoral tissues in a cohort of 60 tissues from osteosarcoma patients using quantitative PCR and immunohistochemistry analysis. The authors also correlated higher expression of XIAP to advanced clinical stage, larger tumor size and metastasis compared to patients expressing lower levels of XIAP. Using MG63 cellular model, a shRNA targeting XIAP efficiently decreased cell proliferation and colony formation, induced apoptosis and cell cycle arrest at G0/G1 phase, displayed enhanced chemosensitivity in combination with doxorubicin or cisplatin, and inhibited tumor growth in nude mice (Qu et al., 2015). Treatment with an aqueous plus a triterpene extract of Viscum album L. led to strong inhibition of proliferation and apoptosis, and enhanced sensitivity to doxorubicin, etoposide and ifosfamide in 143B and Saos-2 cell lines, which were associated with downregulation of XIAP, BIRC5 and CLSPN (Kleinsimon et al., 2017). In addition, the carotenoids fucoxanthin and its metabolite fucoxanthinol induced apoptosis and cell cycle arrest at G1 phase in osteosarcoma human and mouse cell lines by reducing expression of XIAP, BIRC5, BCL2, BCL2L1, CDK4, CDK6, and CCNE1 (Rokkaku et al., 2013). |
| Entity | Ovarian cancer |
| Note | In ovarian cancer models, proteomic analysis demonstrated that XIAP had a positive coefficient correlation with IC50 values, indicating a role for XIAP in drug resistance (Zervantonakis et al., 2017). In agreement, high XIAP levels were inversely correlated with carboplatin response and progression-free survival in patients with ovarian cancer (Zhang et al., 2018). It was also reported that ADPRH, a tumor suppressor gene, was downregulated in 60% of ovarian cancers and promoted upregulation of antiapoptotic proteins, including XIAP (Washington et al., 2015). In ovarian carcinoma cell lines, treatment with phenoxodiol promoted downregulation of XIAP, inhibited autophagy, as evidenced by decreased levels of ATG7, ATG12 and BECN1, and increased cisplatin sensitivity (Miyamoto et al., 2018). Treatment with 10-chlorocanthin-6-one, a cytotoxic agent against HO8910PM cell line, induces apoptosis through activation of PARP1 and caspase-3 cleavage, upregulation of BCL2, and downregulation of XIAP, BIM and BIRC5 (Li et al., 2018). MK-0752, a γ-secretase inhibitor, induced cell growth inhibition through downregulation of XIAP in a dose- and time-dependent manner (Chen et al., 2016). Natural product butein, a polyphenol widely biosynthesized in plants, promoted downregulation of XIAP, BIRC5, BIRC2, and BIRC3 in ovarian cancer cell lines (Yang et al., 2015). Another natural product, an extract of Smilax china L. rhizome, reduced cell proliferation in a dose-dependent manner and induced apoptosis by activation of caspase-3, PARP1 and BAX and by inhibition of NFκB, BCL2, BCL2L1, BIRC2, XIAP and AKT in A2780 cells (Hu et al., 2015). Combined treatment with cisplatin and biothionol enhanced apoptosis through the downregulation of pro-survival factors (XIAP, BCL2 and BCL2L1) in ovarian cancer cell lines (Ayyagari et al., 2017). Similarly, 1-phenylpropadienyl phosphine oxide (PHPO) alone or combined with cisplatin inhibited the PI3K/AKT, MAPK and ATM / CHEK2 (CHK2) pathways, followed by suppression of the antiapoptotic factors BCL2L1, BCL2, and XIAP (Li et al., 2016). Inhibition of NFKB1 and BIRC6-XIAP complex induced by 10H-3,6-diazaphenothiazine treatment reduced metastasis capacity of A2780 cancer cell line (Zhang et al., 2017). In SKOV3/DDP cells, inhibition of NFKB1 and reduced levels of XIAP was also observed after treatment with noscapine, a non-toxic benzylisoquinoline alkaloid extracted from opium (Shen et al., 2015). The regulation of XIAP mediated by miRNAs has been addressed and multiple miRNAs can regulate XIAP via its 3'UTR. For instance, MIR137 sensitized ovarian cancer cells to cisplatin-induced apoptosis via XIAP downregulation in SKOV3 cells (Li et al., 2017). Similar results were observed for MIR155 that mediated cisplatin-induced apoptosis by targeting XIAP (Chen et al., 2016), and for MIR509-3p that can directly target XIAP via its 3'UTR in ovarian cancer cells leading to the inhibition of cell proliferation and increased sensitivity to cisplatin-induced apoptosis (Chen et al., 2016). In addition, it was demonstrated that MIR146A?5p regulated three important antiapoptotic genes, including XIAP, BCL2L2 and BIRC5 via their 3'UTRs. Decreased levels of MIR146A?5p led to increased IC50 values for cisplatin in OVCAR3 and SKOV3 cells (Li et al., 2017). The MIR149 (which also targets XIAP) was significantly downregulated in ovarian cancer tissues and cell lines, for which expression was correlated with patient prognosis and cisplatin chemoresistance (Sun et al., 2018). The downregulation of MIR215 increased cell proliferation, inhibited apoptosis and decreased sensitivity to chemotherapy drugs in ovarian cancer cells through the elevated expression of XIAP (Ge et al., 2016). Extracellular matrix components have been addressed as one factor involved in chemoresistance in ovarian cells. The collagen COL11A1 was demonstrated to activate the signaling pathway SRC/PI3K/AKT/NFκB to induce the expression of three IAPs, including XIAP, which was correlated to the inhibition of cisplatin-induced apoptosis in ovarian cancer cells (Rada et al., 2018). |
| Entity | Pancreatic Cancer |
| Note | XIAP was considered one of the most important factors in chemoresistance of pancreatic carcinoma, and its inhibition increased sensitivity to 5-fluorouracil (5-FU). In pancreatic carcinoma cell line SW1990, XIAP upregulation was observed in cells exposed to 5-FU for up to 30 days. Combined treatment of 5-FU and gemcitabine greatly increased apoptosis index when XIAP was inhibited (LI et al, 2006). High XIAP expression was also associated with poor outcomes in pancreatic carcinoma patients, being an independent predictor and associated with tumor invasion status and histological grading (LI et al., 2013). The treatment with 7-benzylidenenaltrexone maleate (BNTX) combined to TRAIL downregulated XIAP expression, promoting the release of cytochrome c from mitochondria with caspase activation (KIM et al., 2017). The authors suggested that the IAP-mediated resistance of pancreatic cancer cells could be overcome by PKCα/AKT pathway inhibition. A small-molecule IAP antagonist, AT406, significantly inhibited cell survival and proliferation in Panc-1 and Mia-PaCa-2 cell lines, and in primary human pancreatic cancer cells, while displayed no cytotoxicity to pancreatic epithelial cells. Authors noted a degradation of IAP family members (such as XIAP and BIRC2), a release of cytochrome c and higher activity of CASP3 and CASP9 (JIANG et al., 2016). |
| Entity | Prostate cancer |
| Note | The expression of XIAPs in normal human prostate (NP), benign prostatic hyperplasia (BPH), prostatic intraepithelial neoplasia (PIN) and prostatic carcinoma (PC) was evaluated and showed a 20% expression among NPs, 27.27% in BPHs, 33.33% in high-grade PIN and varying from 17.39 to 39.21% in PC. The latter two did not present Gleason variation (Rodriguez-Barriguete et al., 2015). Through immunohistochemical techniques, XIAP expression was seen on human prostate tissue samples, being observed in normal and malignant epithelium, basal cells, but not commonly on stromal fibromuscular cells. XIAP expression was typically diffused in the cytoplasm; however, a discrete supranuclear staining in coarse clusters was observed. On regions of benign prostatic hyperplasia (BPH), XIAP showed the lowest expression. XIAP expression in PC was shown to be significantly higher when compared to PIN, NP and BPH (Seligson et al., 2007). In a small cohort, it was found that higher levels of XIAP was associated with longer relapse-free survival (Krajewska et al., 2003); additionally, in another study, patients with positive immunostaining for XIAP had a better prognosis, which led to questions concerning the pro-tumor role of this IAP in prostate cancer (Rodrèguez-Berriguette et al., 2015). The higher expression of XIAP also predicted the reduced risk of tumor recurrence in dichotomized and continuous variable in univariate analysis. When analyzing patients with primary low-grade cancer, none which had a high expression of XIAP displayed tumor recurrence (n=23). In contrast, patients with low levels of XIAP experienced tumor recurrence (n=89). The same study showed that patients with higher grade or non-confined tumors with an elevated XIAP expression have a better prognosis, when analyzing the group, when compared to those patients that express low levels of XIAP. An example of this finding is that 50% of patients whose tumors were not confined to the organ (n =92) had tumor recurrence, whereas the 12 patients with higher levels of XIAP did not experience recurrence. Patients with low grade tumors and low XIAP levels experienced recurrence (more than 25%), whereas none of the patients with higher levels of XIAP had recurrence of the tumors. In the PSA follow-up, 94% of patients that presented higher levels of XIAP were recurrence-free, against 58% of patients with lower XIAP levels (SELIGSON et al., 2007). XIAP was found to constitutively express on DU145 cells, playing an important role on modulating chemosensitivity (Amantana et al., 2004), the presence of XIAP was also found on PC3 cells on immunohistochemistry assays showing that XIAP was localized mainly on the perinuclear region of this cells (Mceleney et al., 2002). |
| Entity | Thyroid cancer |
| Note | XIAP elevated expression had been associated with a high degree of invasiveness, being related to lymph node metastasis in papillary thyroid cancer (Gu et al., 2010), and also was associated with old age, extrathyroidal extension, tumor size, nodal involvement, tall-cell variant, advanced stage disease, and significantly poor disease-free survival (Hussain et al., 2015). XAF1 (XIAP-associated factor-1) antagonizes XIAP-mediated caspase inhibition. Loss of XAF1 expression correlates with tumor progression. It has been suggested that the G allele of rs34195599 of XAF1 may be a risk factor for the clinicopathological features of papillary thyroid carcinoma (Kim et al., 2013). XIAP expression varied from 48.8% (Hussain et al., 2015) to 83% in papillary thyroid cancer (Xiao et al., 2007) and it was of 25% of insular carcinoma only moderate positive and non-staining in follicular, medullary, anaplastic carcinomas, oncocytic neoplasms (Xiao et al., 2007). In another study XIAP expression was positive in 75% of patients, whose expression was significantly associated with the presence of lateral cervical lymph node metastases. Additionally, XIAP expression was more frequent in BRAFV600E mutated PTCs than in BRAF wild type PTCs (Yim et al., 2014), however no correlation between these two markers were observed (Gu et al., 2009). In papillary thyroid cancer, XIAP expression was associated with phosphorylated AKT, BCL2L1, and Ki67 proteins leading to increase cell proliferation and reduced apoptosis rate that was reverted with treatment with embelin (Hussain et al., 2015). TPC-1 and BCPAP cell lines silenced for NFKB1 and treated with radiation (131I treatment) demonstrated a decrease in cell viability mediated by XIAP and BIRC2 reduction levels and increased is CASP3 levels, demonstrating an induction of apoptosis cascade (Chen et al.,2018). The cell line TPC-1 treated with HSP90 inhibitor promoted cell apoptosis and tumor decreased size caused by inhibition of IAP members, such as XIAP, BIRC5, and BIRC2 (Kim et al., 2016). In follicular thyroid carcinoma, XIAP expression was observed in comparison to non-tumoral thyroid tissue. Additionally, XIAP silencing reverted malignant phenotype, causing a decrease in cell proliferation and an increase in cell apoptosis rate (Werner et al., 2017). In anaplastic thyroid carcinoma, similar results were observed in patients' tissues where XIAP expression was significantly elevated in the invasive area of anaplastic thyroid carcinoma samples, while XIAP expression was negative in either normal thyroid follicular epithelial cells or differentiated papillary thyroid carcinoma. Moreover, silencing XIAP in vitro decreased cancer cell proliferation, migration and invasion (Liu et al., 2017). For anaplastic thyroid carcinoma, it was demonstrated that XIAP repression may be caused by overexpression of miR-618 (Cheng et al., 2014). In medullary thyroid carcinoma elevated BIRC5 or XIAP expression was associated with metastatic condition. XIAP, as well as BIRC5 levels, were negatively associated with patient survival (Werner et al., 2016). |
| To be noted |
| Pharmacological advances targeting XIAP in cancer Development of XIAP inhibitors has been explored in the last few years with significant advances. The use of mimetics has gained considerable attention, especially concerning their pharmacological and physiochemical properties. One strategy refers to employing modifications in amino acids, such as using non-natural amino acids, replacing some residues - e.g. P2 and P3 -, and modifying the C-terminal region. These approaches have been carefully reviewed in Jaquith (2014). Another strategy refers to the development of antagonists of XIAP based on the N-terminus of mature Smac, where a synthetic compound (GDC-0152) revealed interesting results. This compound binds to the XIAP BIR3 domain with K(i) values of 28 nM, activating apoptosis cell death and, consequently, decreasing viability and inhibiting tumor growth of breast cancer cell lines and xenografted tumors, respectively (Flygare at al., 2012). The use of antisense oligonucleotide to target XIAP has also been proposed. One example is the AEG35156, a second-generation 19-mer antisense oligonucleotide, which, in combination with docetaxel, has been undergoing clinical trials for treatment of locally advanced, metastatic, or recurrent solid tumors, such as pancreatic cancer, advanced breast cancer, advanced NSCLC and acute myeloid leukemia. Side effects were limiting factors in the majority of these studies (Tamm, 2006). However, a posterior study demonstrated that it is generally well tolerated in combination with standard chemotherapy in acute myeloid leukemia (Katragadda et al., 2013). In fact, a phase II clinical trial conducted with patients with advanced hepatocellular carcinoma revealed that treatment with AEG35156 in combination with sorafenib yielded positive results, mainly regarding objective responses rates (Lee et al., 2016). Using structure-based drug design, a nonpeptidomimetic small-molecule functioning as a duas antagonist of XIAP and BIRC2, designated AT-IAP, demonstrated IC50 values in the nM range for breast cancer cell lines. Moreover, this compound binds to the BIR 3 domain causing disruption of XIAP and CASP9 and increased levels of cleaved PARP1, indicating activation of apoptosis pathway. Additionally, tumor size reduction was demonstrated in xenograft models (Tamanini et al., 2017). Others XIAP inhibitors have been previously reported, however such inhibition was not always in a direct-manner. This is the case for embelin, a natural product that promotes down-regulation of XIAP and was reported to have promising effects in leukemia (Hu et al., 2014), pancreatic cancer (Mori et al., 2007) and gastric cancer (Wang et al., 2013). Funding: Fundaçao de Amparo à Pesquisa do Estado de Sao Paulo (FAPESP) and Coordenaçao de Aperfeiçoamento de Pessoal de Nivel Superior (CAPES). |
| Bibliography |
| Targeting XIAP for Promoting Cancer Cell Death-The Story of ARTS and SMAC |
| Abbas R, Larisch S |
| Cells 2020 Mar 9;9(3) |
| PMID 32182843 |
| Akt inhibitor MK-2206 promotes anti-tumor activity and cell death by modulation of AIF and Ezrin in colorectal cancer |
| Agarwal E, Chaudhuri A, Leiphrakpam PD, Haferbier KL, Brattain MG, Chowdhury S |
| BMC Cancer 2014 Mar 1;14:145 |
| PMID 24581231 |
| Lambertianic Acid Sensitizes Non-Small Cell Lung Cancers to TRAIL-Induced Apoptosis via Inhibition of XIAP/NF-κB and Activation of Caspases and Death Receptor 4 |
| Ahn DS, Lee HJ, Hwang J, Han H, Kim B, Shim B, Kim SH |
| Int J Mol Sci 2018 May 16;19(5) |
| PMID 29772677 |
| Lymphomas driven by Epstein-Barr virus nuclear antigen-1 (EBNA1) are dependant upon Mdm2 |
| AlQarni S, Al-Sheikh Y, Campbell D, Drotar M, Hannigan A, Boyle S, Herzyk P, Kossenkov A, Armfield K, Jamieson L, Bailo M, Lieberman PM, Tsimbouri P, Wilson JB |
| Oncogene 2018 Jul;37(29):3998-4012 |
| PMID 29691476 |
| X-linked inhibitor of apoptosis protein inhibition induces apoptosis and enhances chemotherapy sensitivity in human prostate cancer cells |
| Amantana A, London CA, Iversen PL, Devi GR |
| Mol Cancer Ther 2004 Jun;3(6):699-707 |
| PMID 15210856 |
| Evaluation of the cytotoxicity of the Bithionol - cisplatin combination in a panel of human ovarian cancer cell lines |
| Ayyagari VN, Hsieh TJ, Diaz-Sylvester PL, Brard L |
| BMC Cancer 2017 Jan 13;17(1):49 |
| PMID 28086831 |
| Clinical and prognostic importance of XIAP and USP8 in advanced stages of non-small cell lung cancer |
| Baykara M, Yaman M, Buyukberber S, Tufan G, Demirci U, Benekli M, Coskun U, Ozet A, Umit Bagriacik E |
| J BUON 2013 Oct-Dec;18(4):921-7 |
| PMID 24344018 |
| Double inhibition of XIAP and Bcl-2 axis is beneficial for retrieving sensitivity of renal cell cancer to apoptosis |
| Bilim V, Yuuki K, Itoi T, Muto A, Kato T, Nagaoka A, Motoyama T, Tomita Y |
| Br J Cancer 2008 Mar 11;98(5):941-9 |
| PMID 18283311 |
| SAHA and S116836, a novel tyrosine kinase inhibitor, synergistically induce apoptosis in imatinib-resistant chronic myelogenous leukemia cells |
| Bu Q, Cui L, Li J, Du X, Zou W, Ding K, Pan J |
| Cancer Biol Ther 2014 Jul;15(7):951-62 |
| PMID 24759597 |
| A potential role of X-linked inhibitor of apoptosis protein in mitochondrial membrane permeabilization and its implication in cancer therapy |
| Chaudhary AK, Yadav N, Bhat TA, O'Malley J, Kumar S, Chandra D |
| Drug Discov Today 2016 Jan;21(1):38-47 |
| PMID 26232549 |
| Co-expression of XIAP and cyclin D1 complex correlates with a poor prognosis in patients with hepatocellular carcinoma |
| Che Y, Ye F, Xu R, Qing H, Wang X, Yin F, Cui M, Burstein D, Jiang B, Zhang DY |
| Am J Pathol 2012 May;180(5):1798-807 |
| PMID 22429965 |
| Effects of nuclear factorB on the uptake of 131iodine and apoptosis of thyroid carcinoma cells |
| Chen F, Yin S, Zhu J, Jia L, Zhang H, Yang C, Liu C, Deng Z |
| Mol Med Rep 2018 Apr;17(4):4959-4964 |
| PMID 29393421 |
| Blockade of Inhibitors of Apoptosis Proteins in Combination with Conventional Chemotherapy Leads to Synergistic Antitumor Activity in Medulloblastoma and Cancer Stem-Like Cells |
| Chen SM, Li YY, Tu CH, Salazar N, Tseng YY, Huang SF, Hsieh LL, Lui TN |
| PLoS One 2016 Aug 18;11(8):e0161299 |
| PMID 27537345 |
| Targeting inhibitors of apoptosis proteins suppresses medulloblastoma cell proliferation via G2/M phase arrest and attenuated neddylation of p21 |
| Chen SM, Lin TK, Tseng YY, Tu CH, Lui TN, Huang SF, Hsieh LL, Li YY |
| Cancer Med 2018 Aug;7(8):3988-4003 |
| PMID 29984917 |
| MicroRNA-155 promotes apoptosis in SKOV3, A2780, and primary cultured ovarian cancer cells |
| Chen W, Huang L, Hao C, Zeng W, Luo X, Li X, Zhou L, Jiang S, Chen Z, He Y |
| Tumour Biol 2016 Jul;37(7):9289-99 |
| PMID 26779627 |
| MiR-618 inhibits anaplastic thyroid cancer by repressing XIAP in one ATC cell line |
| Cheng Q, Zhang X, Xu X, Lu X |
| Ann Endocrinol (Paris) 2014 Sep;75(4):187-93 |
| PMID 25145559 |
| Evaluation of the Expression of the Inhibitor of Apoptosis Protein Family and Human Telomerase Reverse Transcriptase in Patients With Advanced Colorectal Adenoma |
| Choi JY, Yoon H, Na G, Choi YJ, Shin CM, Park YS, Kim N, Lee DH |
| J Cancer Prev 2017 Jun;22(2):98-102 |
| PMID 28698863 |
| Histone deacetylase inhibitor belinostat represses survivin expression through reactivation of transforming growth factor beta (TGFbeta) receptor II leading to cancer cell death |
| Chowdhury S, Howell GM, Teggart CA, Chowdhury A, Person JJ, Bowers DM, Brattain MG |
| J Biol Chem 2011 Sep 2;286(35):30937-48 |
| PMID 21757750 |
| The probiotic Propionibacterium freudenreichii as a new adjuvant for TRAIL-based therapy in colorectal cancer |
| Cousin FJ, Jouan-Lanhouet S, Théret N, Brenner C, Jouan E, Le Moigne-Muller G, Dimanche-Boitrel MT, Jan G |
| Oncotarget 2016 Feb 9;7(6):7161-78 |
| PMID 26771233 |
| Bufalin and 5-fluorouracil synergistically induce apoptosis in colorectal cancer cells |
| Dai XY, Zhou BF, Xie YY, Lou J, Li KQ |
| Oncol Lett 2018 May;15(5):8019-8026 |
| PMID 29849804 |
| Blockade of histone deacetylase inhibitor-induced RelA/p65 acetylation and NF-kappaB activation potentiates apoptosis in leukemia cells through a process mediated by oxidative damage, XIAP downregulation, and c-Jun N-terminal kinase 1 activation |
| Dai Y, Rahmani M, Dent P, Grant S |
| Mol Cell Biol 2005 Jul;25(13):5429-44 |
| PMID 15964800 |
| Impact of XIAP protein levels on the survival of myeloma cells |
| Desplanques G, Giuliani N, Delsignore R, Rizzoli V, Bataille R, Barillé-Nion S |
| Haematologica 2009 Jan;94(1):87-93 |
| PMID 19001278 |
| Death receptor 5 (DR5) and a 5-gene apoptotic biomarker panel with significant differential diagnostic potential in colorectal cancer |
| Devetzi M, Kosmidou V, Vlassi M, Perysinakis I, Aggeli C, Choreftaki T, Zografos GN, Pintzas A |
| Sci Rep 2016 Nov 9;6:36532 |
| PMID 27827395 |
| Clinicopathological and functional implications of the inhibitor of apoptosis proteins survivin and XIAP in esophageal cancer |
| Dizdar L, Jünemann LM, Werner TA, Verde PE, Baldus SE, Stoecklein NH, Knoefel WT, Krieg A |
| Oncol Lett 2018 Mar;15(3):3779-3789 |
| PMID 29467895 |
| Survivin and XIAP expression in distinct tumor compartments of surgically resected gastric cancer: XIAP as a prognostic marker in diffuse and mixed type adenocarcinomas |
| Dizdar L, Tomczak M, Werner TA, Safi SA, Riemer JC, Verde PE, Stoecklein NH, Knoefel WT, Krieg A |
| Oncol Lett 2017 Dec;14(6):6847-6856 |
| PMID 29109763 |
| An IAP-IAP complex inhibits apoptosis |
| Dohi T, Okada K, Xia F, Wilford CE, Samuel T, Welsh K, Marusawa H, Zou H, Armstrong R, Matsuzawa S, Salvesen GS, Reed JC, Altieri DC |
| J Biol Chem 2004 Aug 13;279(33):34087-90 |
| PMID 15218035 |
| Human inhibitor of apoptosis proteins: why XIAP is the black sheep of the family |
| Eckelman BP, Salvesen GS, Scott FL |
| EMBO Rep 2006 Oct;7(10):988-94 |
| PMID 17016456 |
| Degradation of Bcl-2 by XIAP and ARTS Promotes Apoptosis |
| Edison N, Curtz Y, Paland N, Mamriev D, Chorubczyk N, Haviv-Reingewertz T, Kfir N, Morgenstern D, Kupervaser M, Kagan J, Kim HT, Larisch S |
| Cell Rep 2017 Oct 10;21(2):442-454 |
| PMID 29020630 |
| XIAP-targeting drugs re-sensitize PIK3CA-mutated colorectal cancer cells for death receptor-induced apoptosis |
| Ehrenschwender M, Bittner S, Seibold K, Wajant H |
| Cell Death Dis 2014 Dec 11;5:e1570 |
| PMID 25501831 |
| Differential control of growth, apoptotic activity and gene expression in human colon cancer cells by extracts derived from medicinal herbs, Rhazya stricta and Zingiber officinale and their combination |
| Elkady AI, Hussein RA, Abu-Zinadah OA |
| World J Gastroenterol 2014 Nov 7;20(41):15275-88 |
| PMID 25386076 |
| Immunohistochemical detection of XIAP in melanoma |
| Emanuel PO, Phelps RG, Mudgil A, Shafir M, Burstein DE |
| J Cutan Pathol 2008 Mar;35(3):292-7 |
| PMID 18251743 |
| USP9X stabilizes XIAP to regulate mitotic cell death and chemoresistance in aggressive B-cell lymphoma |
| Engel K, Rudelius M, Slawska J, Jacobs L, Ahangarian Abhari B, Altmann B, Kurutz J, Rathakrishnan A, Fernández-Sáiz V, Brunner A, Targosz BS, Loewecke F, Gloeckner CJ, Ueffing M, Fulda S, Pfreundschuh M, Trümper L, Klapper W, Keller U, Jost PJ, Rosenwald A, Peschel C, Bassermann F |
| EMBO Mol Med 2016 Aug 1;8(8):851-62 |
| PMID 27317434 |
| Smac mimetic LBW242 sensitizes XIAP-overexpressing neuroblastoma cells for TNF-α-independent apoptosis |
| Eschenburg G, Eggert A, Schramm A, Lode HN, Hundsdoerfer P |
| Cancer Res 2012 May 15;72(10):2645-56 |
| PMID 22491673 |
| Inhibitors of apoptosis proteins in human cervical cancer |
| Espinosa M, Cantú D, Herrera N, Lopez CM, De la Garza JG, Maldonado V, Melendez-Zajgla J |
| BMC Cancer 2006 Feb 27;6:45 |
| PMID 16504151 |
| XIAP Regulation by MNK Links MAPK and NFκB Signaling to Determine an Aggressive Breast Cancer Phenotype |
| Evans MK, Brown MC, Geradts J, Bao X, Robinson TJ, Jolly MK, Vermeulen PB, Palmer GM, Gromeier M, Levine H, Morse MA, Van Laere SJ, Devi GR |
| Cancer Res 2018 Apr 1;78(7):1726-1738 |
| PMID 29351901 |
| Specific inhibition of p110α subunit of PI3K: putative therapeutic strategy for KRAS mutant colorectal cancers |
| Fernandes MS, Melo S, Velho S, Carneiro P, Carneiro F, Seruca R |
| Oncotarget 2016 Oct 18;7(42):68546-68558 |
| PMID 27602501 |
| Expression of X-linked inhibitor of apoptosis as a novel prognostic marker in radically resected non-small cell lung cancer patients |
| Ferreira CG, van der Valk P, Span SW, Ludwig I, Smit EF, Kruyt FA, Pinedo HM, van Tinteren H, Giaccone G |
| Clin Cancer Res 2001 Aug;7(8):2468-74 |
| PMID 11489828 |
| Discovery of a potent small-molecule antagonist of inhibitor of apoptosis (IAP) proteins and clinical candidate for the treatment of cancer (GDC-0152) |
| Flygare JA, Beresini M, Budha N, Chan H, Chan IT, Cheeti S, Cohen F, Deshayes K, Doerner K, Eckhardt SG, Elliott LO, Feng B, Franklin MC, Reisner SF, Gazzard L, Halladay J, Hymowitz SG, La H, LoRusso P, Maurer B, Murray L, Plise E, Quan C, Stephan JP, Young SG, Tom J, Tsui V, Um J, Varfolomeev E, Vucic D, Wagner AJ, Wallweber HJ, Wang L, Ware J, Wen Z, Wong H, Wong JM, Wong M, Wong S, Yu R, Zobel K, Fairbrother WJ |
| J Med Chem 2012 May 10;55(9):4101-13 |
| PMID 22413863 |
| Site-specific gene expression patterns in oral cancer |
| Frohwitter G, Buerger H, Korsching E, van Diest PJ, Kleinheinz J, Fillies T |
| Head Face Med 2017 May 10;13(1):6 |
| PMID 28486965 |
| Vincristine resistance in relapsed neuroblastoma can be efficiently overcome by Smac mimetic LCL161 treatment |
| Frommann K, Appl B, Hundsdoerfer P, Reinshagen K, Eschenburg G |
| J Pediatr Surg 2018 Oct;53(10):2059-2064 |
| PMID 29455885 |
| XIAP inhibitor Embelin inhibits bladder cancer survival and invasion in vitro |
| Fu X, Pang X, Qi H, Chen S, Li Y, Tan W |
| Clin Transl Oncol 2016 Mar;18(3):277-82 |
| Puerarin induced in mantle cell lymphoma apoptosis and its possible mechanisms involving multi-signaling pathway |
| Gan M, Yin X |
| Cell Biochem Biophys 2015 Jan;71(1):367-73 |
| PMID 25173778 |
| [Expression and subcellular localization of XIAP and XAF1 in human normal oral keratinocytes and Tca8113 cells] |
| Gao WX, Wang X, Wei XF, Chen YX, Zhang J, Zhu LK |
| Zhonghua Kou Qiang Yi Xue Za Zhi 2006 Nov;41(11):682-3 |
| PMID 17331366 |
| Prognostic Value of XIAP Level in Patients with Various Cancers: A Systematic Review and Meta-Analysis |
| Gao X, Zhang L, Wei Y, Yang Y, Li J, Wu H, Yin Y |
| J Cancer 2019 Feb 26;10(6):1528-1537 |
| PMID 31031863 |
| miR-215 functions as a tumor suppressor in epithelial ovarian cancer through regulation of the X-chromosome-linked inhibitor of apoptosis |
| Ge G, Zhang W, Niu L, Yan Y, Ren Y, Zou Y |
| Oncol Rep 2016 Mar;35(3):1816-22 |
| PMID 26676658 |
| Inhibition of IAP's and activation of p53 leads to caspase-dependent apoptosis in gastric cancer cells treated with Scutellarein |
| Gowda Saralamma VV, Lee HJ, Raha S, Lee WS, Kim EH, Lee SJ, Heo JD, Won C, Kang CK, Kim GS |
| Oncotarget 2017 Dec 11;9(5):5993-6006 |
| PMID 29464049 |
| BRAFV600E mutation and X-linked inhibitor of apoptosis expression in papillary thyroid carcinoma |
| Gu LQ, Li FY, Zhao L, Liu Y, Zang XX, Wang TX, Chen HP, Ning G, Zhao YJ |
| Thyroid 2009 Apr;19(4):347-54 |
| PMID 19355825 |
| Protein profiling of alpha-fetoprotein producing gastric adenocarcinoma |
| He L, Ye F, Qu L, Wang D, Cui M, Wei C, Xing Y, Lee P, Suo J, Zhang DY |
| Oncotarget 2016 May 10;7(19):28448-59 |
| PMID 27057629 |
| The SMAC mimetic BV6 sensitizes colorectal cancer cells to ionizing radiation by interfering with DNA repair processes and enhancing apoptosis |
| Hehlgans S, Oppermann J, Reichert S, Fulda S, Rödel C, Rödel F |
| Radiat Oncol 2015 Sep 17;10:198 |
| PMID 26383618 |
| The Role of cIAP1 and XIAP in Apoptosis Induced by Tumor Necrosis Factor Alpha in Esophageal Squamous Cell Carcinoma Cells |
| Hikami S, Shiozaki A, Kitagawa-Juge M, Ichikawa D, Kosuga T, Konishi H, Komatsu S, Fujiwara H, Okamoto K, Otsuji E |
| Dig Dis Sci 2017 Mar;62(3):652-659 |
| PMID 28050781 |
| Targeting X-linked inhibitor of apoptosis protein to increase the efficacy of endoplasmic reticulum stress-induced apoptosis for melanoma therapy |
| Hiscutt EL, Hill DS, Martin S, Kerr R, Harbottle A, Birch-Machin M, Redfern CP, Fulda S, Armstrong JL, Lovat PE |
| J Invest Dermatol 2010 Sep;130(9):2250-8 |
| PMID 20520630 |
| Functional characterization of the X-linked inhibitor of apoptosis (XIAP) internal ribosome entry site element: role of La autoantigen in XIAP translation |
| Holcik M, Korneluk RG |
| Mol Cell Biol 2000 Jul;20(13):4648-57 |
| PMID 10848591 |
| A new internal-ribosome-entry-site motif potentiates XIAP-mediated cytoprotection |
| Holcik M, Lefebvre C, Yeh C, Chow T, Korneluk RG |
| Nat Cell Biol 1999 Jul;1(3):190-2 |
| PMID 10559907 |
| The XIAP inhibitor Embelin enhances TRAIL-induced apoptosis in human leukemia cells by DR4 and DR5 upregulation |
| Hu R, Yang Y, Liu Z, Jiang H, Zhu K, Li J, Xu W |
| Tumour Biol 2015 Feb;36(2):769-77 |
| PMID 25293521 |
| miR-122 Targets X-Linked Inhibitor of Apoptosis Protein to Sensitize Oxaliplatin-Resistant Colorectal Cancer Cells to Oxaliplatin-Mediated Cytotoxicity |
| Hua Y, Zhu Y, Zhang J, Zhu Z, Ning Z, Chen H, Liu L, Chen Z, Meng Z |
| Cell Physiol Biochem 2018;51(5):2148-2159 |
| PMID 30522111 |
| Upregulation of SQSTM1/p62 contributes to nickel-induced malignant transformation of human bronchial epithelial cells |
| Huang H, Zhu J, Li Y, Zhang L, Gu J, Xie Q, Jin H, Che X, Li J, Huang C, Chen LC, Lyu J, Gao J, Huang C |
| Autophagy 2016 Oct 2;12(10):1687-1703 |
| PMID 27467530 |
| Altered expression profile of apoptosis-related molecules correlated with clinicopathological factors in non-small-cell lung cancer |
| Huang JQ, Liang HL, Jin TE, Xie Z |
| Int J Clin Exp Pathol 2015 Sep 1;8(9):11278-86 |
| PMID 26647102 |
| XIAP facilitates breast and colon carcinoma growth via promotion of p62 depletion through ubiquitination-dependent proteasomal degradation |
| Huang X, Wang XN, Yuan XD, Wu WY, Lobie PE, Wu Z |
| Oncogene 2019 Feb;38(9):1448-1460 |
| PMID 30275562 |
| XIAP expression is post-transcriptionally upregulated in childhood ALL and is associated with glucocorticoid response in T-cell ALL |
| Hundsdoerfer P, Dietrich I, Schmelz K, Eckert C, Henze G |
| Pediatr Blood Cancer 2010 Aug;55(2):260-6 |
| PMID 20582956 |
| XIAP over-expression is an independent poor prognostic marker in Middle Eastern breast cancer and can be targeted to induce efficient apoptosis |
| Hussain AR, Siraj AK, Ahmed M, Bu R, Pratheeshkumar P, Alrashed AM, Qadri Z, Ajarim D, Al-Dayel F, Beg S, Al-Kuraya KS |
| BMC Cancer 2017 Sep 11;17(1):640 |
| PMID 28893228 |
| X-linked inhibitor of apoptosis deficiency in the TRAMP mouse prostate cancer model |
| Hwang C, Oetjen KA, Kosoff D, Wojno KJ, Albertelli MA, Dunn RL, Robins DM, Cooney KA, Duckett CS |
| Cell Death Differ 2008 May;15(5):831-40 |
| PMID 18259199 |
| Staying Alive or Going to Die During Terminal Senescence-An Enigma Surrounding Yield Stability |
| Jagadish KS, Kavi Kishor PB, Bahuguna RN, von Wirén N, Sreenivasulu N |
| Front Plant Sci 2015 Nov 30;6:1070 |
| PMID 26648957 |
| Targeting the inhibitor of Apoptosis Protein BIR3 binding domains |
| Jaquith JB |
| Pharm Pat Anal 2014 May;3(3):297-312 |
| PMID 24998289 |
| The small-molecule IAP antagonist AT406 inhibits pancreatic cancer cells in vitro and in vivo |
| Jiang Y, Meng Q, Chen B, Shen H, Yan B, Sun B |
| Biochem Biophys Res Commun 2016 Sep 9;478(1):293-299 |
| PMID 27387230 |
| XIAP RING domain mediates miR-4295 expression and subsequently inhibiting p63α protein translation and promoting transformation of bladder epithelial cells |
| Jin H, Xu J, Guo X, Huang H, Li J, Peng M, Zhu J, Tian Z, Wu XR, Tang MS, Huang C |
| Oncotarget 2016 Aug 30;7(35):56540-56557 |
| PMID 27447744 |
| Negative correlation between X-linked inhibitors of apoptosis and second mitochondria-derived activator of caspase expression levels in cervical carcinoma and cervical intraepithelial neoplasia |
| Jin XJ, Cai PS, Zhu SP, Wang LJ, Zhu H |
| Oncol Lett 2017 Nov;14(5):5340-5346 |
| PMID 29113168 |
| Ciglitazone induces caspase-independent apoptosis through down-regulation of XIAP and survivin in human glioma cells |
| Kang DW, Choi CH, Park JY, Kang SK, Kim YK |
| Neurochem Res 2008 Mar;33(3):551-61 |
| PMID 17940898 |
| NF-kappaB at the crossroads of life and death |
| Karin M, Lin A |
| Nat Immunol 2002 Mar;3(3):221-7 |
| PMID 11875461 |
| XIAP antisense therapy with AEG 35156 in acute myeloid leukemia |
| Katragadda L, Carter BZ, Borthakur G |
| Expert Opin Investig Drugs 2013 May;22(5):663-70 |
| PMID 23586880 |
| Synergistic cytotoxicity of BIIB021 with triptolide through suppression of PI3K/Akt/mTOR and NF-κB signal pathways in thyroid carcinoma cells |
| Kim SH, Kang JG, Kim CS, Ihm SH, Choi MG, Yoo HJ, Lee SJ |
| Biomed Pharmacother 2016 Oct;83:22-32 |
| PMID 27470546 |
| Missense polymorphisms in XIAP-associated factor-1 (XAF1) and risk of papillary thyroid cancer: correlation with clinicopathological features |
| Kim SK, Park HJ, Seok H, Jeon HS, Kim JW, Chung JH, Kwon KH, Woo SH, Lee BW, Baik HH |
| Anticancer Res 2013 May;33(5):2205-10 |
| PMID 23645777 |
| Downregulation of X-linked inhibitor of apoptosis protein by '7-Benzylidenenaltrexone maleate' sensitizes pancreatic cancer cells to TRAIL-induced apoptosis |
| Kim SY, Park S, Yoo S, Rho JK, Jun ES, Chang S, Kim KK, Kim SC, Kim I |
| Oncotarget 2017 May 12;8(37):61057-61071 |
| PMID 28977846 |
| Tumor necrosis factor-α-induced apoptosis of gastric cancer MKN28 cells: accelerated degradation of the inhibitor of apoptosis family members |
| Kitagawa M, Shiozaki A, Ichikawa D, Nakashima S, Kosuga T, Konishi H, Komatsu S, Fujiwara H, Okamoto K, Otsuji E |
| Arch Biochem Biophys 2015 Jan 15;566:43-8 |
| PMID 25513960 |
| ViscumTT induces apoptosis and alters IAP expression in osteosarcoma in vitro and has synergistic action when combined with different chemotherapeutic drugs |
| Kleinsimon S, Kauczor G, Jaeger S, Eggert A, Seifert G, Delebinski C |
| BMC Complement Altern Med 2017 Jan 7;17(1):26 |
| PMID 28061770 |
| Elevated expression of inhibitor of apoptosis proteins in prostate cancer |
| Krajewska M, Krajewski S, Banares S, Huang X, Turner B, Bubendorf L, Kallioniemi OP, Shabaik A, Vitiello A, Peehl D, Gao GJ, Reed JC |
| Clin Cancer Res 2003 Oct 15;9(13):4914-25 |
| PMID 14581366 |
| A Smac mimetic augments the response of urothelial cancer cells to gemcitabine and cisplatin |
| Lee EK, Jinesh G G, Laing NM, Choi W, McConkey DJ, Kamat AM |
| Cancer Biol Ther 2013 Sep;14(9):812-22 |
| PMID 23792592 |
| Randomized Phase II Study of the X-linked Inhibitor of Apoptosis (XIAP) Antisense AEG35156 in Combination With Sorafenib in Patients With Advanced Hepatocellular Carcinoma (HCC) |
| Lee FA, Zee BC, Cheung FY, Kwong P, Chiang CL, Leung KC, Siu SW, Lee C, Lai M, Kwok C, Chong M, Jolivet J, Tung S |
| Am J Clin Oncol 2016 Dec;39(6):609-613 |
| PMID 24977690 |
| Mithramycin A sensitizes cancer cells to TRAIL-mediated apoptosis by down-regulation of XIAP gene promoter through Sp1 sites |
| Lee TJ, Jung EM, Lee JT, Kim S, Park JW, Choi KS, Kwon TK |
| Mol Cancer Ther 2006 Nov;5(11):2737-46 |
| PMID 17121920 |
| Ezrin expression and cell survival regulation in colorectal cancer |
| Leiphrakpam PD, Rajput A, Mathiesen M, Agarwal E, Lazenby AJ, Are C, Brattain MG, Chowdhury S |
| Cell Signal 2014 May;26(5):868-79 |
| PMID 24462708 |
| XIAP expression is associated with pancreatic carcinoma outcome |
| Li S, Sun J, Yang J, Zhang L, Wang L, Wang X, Guo Z |
| Mol Clin Oncol 2013 Mar;1(2):305-308 |
| PMID 24649165 |
| Analysis of the chemotherapeutic effects of a propadiene compound on malignant ovarian cancer cells |
| Li S, Yang L, Wang J, Liang F, Chang B, Gu H, Wang H, Yang G, Chen Y |
| Oncotarget 2016 Aug 30;7(35):57145-57159 |
| PMID 27494891 |
| Synthesis and inhibitory effect of 10-chlorocanthin-6-one on ovarian cancer HO8910PM cells |
| Li W, Chen Y, Sheng Y, Xie Z, Tang Y |
| Biotechnol Lett 2018 Jan;40(1):23-30 |
| PMID 28948407 |
| Treatment of malignant melanoma by downregulation of XIAP and overexpression of TRAIL with a conditionally replicating oncolytic adenovirus |
| Li XQ, Ke XZ, Wang YM |
| Asian Pac J Cancer Prev 2012;13(4):1471-6 |
| PMID 22799350 |
| Dual targeting of survivin and X-linked inhibitor of apoptosis protein suppresses the growth and promotes the apoptosis of gastric cancer HGC-27 cells |
| Li Y, Gao W, Ma Y, Zhu G, Chen F, Qu H |
| Oncol Lett 2018 Sep;16(3):3489-3498 |
| PMID 30127953 |
| XIAP is related to the chemoresistance and inhibited its expression by RNA interference sensitize pancreatic carcinoma cells to chemotherapeutics |
| Li Y, Jian Z, Xia K, Li X, Lv X, Pei H, Chen Z, Li J |
| Pancreas 2006 Apr;32(3):288-96 |
| PMID 16628085 |
| Identification of XAF1 as an antagonist of XIAP anti-Caspase activity |
| Liston P, Fong WG, Kelly NL, Toji S, Miyazaki T, Conte D, Tamai K, Craig CG, McBurney MW, Korneluk RG |
| Nat Cell Biol 2001 Feb;3(2):128-33 |
| PMID 11175744 |
| Anti-apoptotic proteins, apoptotic and proliferative parameters and their prognostic significance in cervical carcinoma |
| Liu SS, Tsang BK, Cheung AN, Xue WC, Cheng DK, Ng TY, Wong LC, Ngan HY |
| Eur J Cancer 2001 Jun;37(9):1104-10 |
| PMID 11378340 |
| Protein signature for non-small cell lung cancer prognosis |
| Liu W, Wu Y, Wang L, Gao L, Wang Y, Liu X, Zhang K, Song J, Wang H, Bayer TA, Glaser L, Sun Y, Zhang W, Cutaia M, Zhang DY, Ye F |
| Am J Cancer Res 2014 May 26;4(3):256-69 |
| PMID 24959380 |
| Inhibition of X-linked inhibitor of apoptosis protein suppresses tumorigenesis and enhances chemosensitivity in anaplastic thyroid carcinoma |
| Liu Y, Zhang B, Shi T, Qin H |
| Oncotarget 2017 Sep 28;8(56):95764-95772 |
| PMID 29221164 |
| Detachment-induced upregulation of XIAP and cIAP2 delays anoikis of intestinal epithelial cells |
| Liu Z, Li H, Wu X, Yoo BH, Yan SR, Stadnyk AW, Sasazuki T, Shirasawa S, LaCasse EC, Korneluk RG, Rosen KV |
| Oncogene 2006 Dec 14;25(59):7680-90 |
| PMID 16799641 |
| XIAP induces NF-kappaB activation via the BIR1/TAB1 interaction and BIR1 dimerization |
| Lu M, Lin SC, Huang Y, Kang YJ, Rich R, Lo YC, Myszka D, Han J, Wu H |
| Mol Cell 2007 Jun 8;26(5):689-702 |
| PMID 17560374 |
| Down-regulation of BAX gene during carcinogenesis and acquisition of resistance to 5-FU in colorectal cancer |
| Manoochehri M, Karbasi A, Bandehpour M, Kazemi B |
| Pathol Oncol Res 2014 Apr;20(2):301-7 |
| PMID 24122668 |
| Inhibitors of apoptosis proteins in prostate cancer cell lines |
| McEleny KR, Watson RW, Coffey RN, O'Neill AJ, Fitzpatrick JM |
| Prostate 2002 May 1;51(2):133-40 |
| PMID 11948968 |
| Phenoxodiol Increases Cisplatin Sensitivity in Ovarian Clear Cancer Cells Through XIAP Down-regulation and Autophagy Inhibition |
| Miyamoto M, Takano M, Aoyama T, Soyama H, Ishibashi H, Kato K, Iwahashi H, Takasaki K, Kuwahara M, Matuura H, Sakamoto T, Yoshikawa T, Furuya K |
| Anticancer Res 2018 Jan;38(1):301-306 |
| PMID 29277787 |
| Overexpression of XIAP expression in renal cell carcinoma predicts a worse prognosis |
| Mizutani Y, Nakanishi H, Li YN, Matsubara H, Yamamoto K, Sato N, Shiraishi T, Nakamura T, Mikami K, Okihara K, Takaha N, Ukimura O, Kawauchi A, Nonomura N, Bonavida B, Miki T |
| Int J Oncol 2007 Apr;30(4):919-25 |
| PMID 17332931 |
| Targeting the intrinsic apoptosis pathway as a strategy for melanoma therapy |
| Mohana-Kumaran N, Hill DS, Allen JD, Haass NK |
| Pigment Cell Melanoma Res 2014 Jul;27(4):525-39 |
| PMID 24655414 |
| Differential sensitivity to apoptosome apparatus activation in non-small cell lung carcinoma and the lung |
| Moravcikova E, Krepela E, Prochazka J, Benkova K, Pauk N |
| Int J Oncol 2014 May;44(5):1443-54 |
| PMID 24626292 |
| Immunohistochemical detection of X-linked inhibitor of apoptosis in head and neck squamous cell carcinoma |
| Nagi C, Xiao GQ, Li G, Genden E, Burstein DE |
| Ann Diagn Pathol 2007 Dec;11(6):402-6 |
| PMID 18022123 |
| Regulation of ubiquitin transfer by XIAP, a dimeric RING E3 ligase |
| Nakatani Y, Kleffmann T, Linke K, Condon SM, Hinds MG, Day CL |
| Biochem J 2013 Mar 15;450(3):629-38 |
| PMID 23259674 |
| FOXM1 targets XIAP and Survivin to modulate breast cancer survival and chemoresistance |
| Nestal de Moraes G, Delbue D, Silva KL, Robaina MC, Khongkow P, Gomes AR, Zona S, Crocamo S, Mencalha AL, Magalhães LM, Lam EW, Maia RC |
| Cell Signal 2015 Dec;27(12):2496-505 |
| PMID 26404623 |
| X-linked inhibitor of apoptosis protein - a critical death resistance regulator and therapeutic target for personalized cancer therapy |
| Obexer P, Ausserlechner MJ |
| Front Oncol 2014 Jul 28;4:197 |
| PMID 25120954 |
| Identification of novel biomarkers in neuroblastoma associated with the risk for bone marrow metastasis: a pilot study |
| Osman J, Galli S, Hanafy M, Tang X, Ahmed A |
| Clin Transl Oncol 2013 Nov;15(11):953-8 |
| PMID 23553333 |
| miR-509-3p is clinically significant and strongly attenuates cellular migration and multi-cellular spheroids in ovarian cancer |
| Pan Y, Robertson G, Pedersen L, Lim E, Hernandez-Herrera A, Rowat AC, Patil SL, Chan CK, Wen Y, Zhang X, Basu-Roy U, Mansukhani A, Chu A, Sipahimalani P, Bowlby R, Brooks D, Thiessen N, Coarfa C, Ma Y, Moore RA, Schein JE, Mungall AJ, Liu J, Pecot CV, Sood AK, Jones SJ, Marra MA, Gunaratne PH |
| Oncotarget 2016 May 3;7(18):25930-48 |
| PMID 27036018 |
| Anticancer Effect of Ursodeoxycholic Acid in Human Oral Squamous Carcinoma HSC-3 Cells through the Caspases |
| Pang L, Zhao X, Liu W, Deng J, Tan X, Qiu L |
| Nutrients 2015 May 5;7(5):3200-18 |
| PMID 25951128 |
| The correlation between XIAP gene polymorphisms and esophageal squamous cell carcinoma susceptibility and prognosis in a Chinese population |
| Peng H, Wang LG, Wang XZ, Liu AJ |
| Pathol Res Pract 2017 Dec;213(12):1482-1488 |
| PMID 29037837 |
| Indole-3-carbinol induces cMYC and IAP-family downmodulation and promotes apoptosis of Epstein-Barr virus (EBV)-positive but not of EBV-negative Burkitt's lymphoma cell lines |
| Perez-Chacon G, de Los Rios C, Zapata JM |
| Pharmacol Res 2014 Nov;89:46-56 |
| PMID 25180456 |
| Apoptosis as anticancer mechanism: function and dysfunction of its modulators and targeted therapeutic strategies |
| Pistritto G, Trisciuoglio D, Ceci C, Garufi A, D'Orazi G |
| Aging (Albany NY) 2016 Apr;8(4):603-19 |
| PMID 27019364 |
| The G protein-coupled P2Y receptor promotes colorectal cancer tumorigenesis by inhibiting apoptosis |
| Placet M, Arguin G, Molle CM, Babeu JP, Jones C, Carrier JC, Robaye B, Geha S, Boudreau F, Gendron FP |
| Biochim Biophys Acta Mol Basis Dis 2018 May;1864(5 Pt A):1539-1551 |
| PMID 29454075 |
| XIAP inhibits mature Smac-induced apoptosis by degrading it through ubiquitination in NSCLC |
| Qin S, Yang C, Zhang B, Li X, Sun X, Li G, Zhang J, Xiao G, Gao X, Huang G, Wang P, Ren H |
| Int J Oncol 2016 Oct;49(4):1289-96 |
| PMID 27498621 |
| Characterization of an inhibitor of apoptosis protein in Crassostrea gigas clarifies its role in apoptosis and immune defense |
| Qu T, Zhang L, Wang W, Huang B, Li Y, Zhu Q, Li L, Zhang G |
| Dev Comp Immunol 2015 Jul;51(1):74-8 |
| PMID 25720977 |
| Inhibitor of apoptosis proteins (IAPs) mediate collagen type XI alpha 1-driven cisplatin resistance in ovarian cancer |
| Rada M, Nallanthighal S, Cha J, Ryan K, Sage J, Eldred C, Ullo M, Orsulic S, Cheon DJ |
| Oncogene 2018 Aug;37(35):4809-4820 |
| PMID 29769618 |
| IAP-IAP complexes required for apoptosis resistance of C |
| Rajalingam K, Sharma M, Paland N, Hurwitz R, Thieck O, Oswald M, Machuy N, Rudel T |
| trachomatis-infected cells PLoS Pathog |
| PMID 17069460 |
| XIAP expression is an independent prognostic marker in clear-cell renal carcinomas |
| Ramp U, Krieg T, Caliskan E, Mahotka C, Ebert T, Willers R, Gabbert HE, Gerharz CD |
| Hum Pathol 2004 Aug;35(8):1022-8 |
| PMID 15297970 |
| Siva1 is a XIAP-interacting protein that balances NFkappaB and JNK signalling to promote apoptosis |
| Resch U, Schichl YM, Winsauer G, Gudi R, Prasad K, de Martin R |
| J Cell Sci 2009 Aug 1;122(Pt 15):2651-61 |
| PMID 19584092 |
| Prognostic value of inhibitors of apoptosis proteins (IAPs) and caspases in prostate cancer: caspase-3 forms and XIAP predict biochemical progression after radical prostatectomy |
| Rodríguez-Berriguete G, Torrealba N, Ortega MA, Martínez-Onsurbe P, Olmedilla G, Paniagua R, Guil-Cid M, Fraile B, Royuela M |
| BMC Cancer 2015 Oct 27;15:809 |
| PMID 26507126 |
| Anticancer effects of marine carotenoids, fucoxanthin and its deacetylated product, fucoxanthinol, on osteosarcoma |
| Rokkaku T, Kimura R, Ishikawa C, Yasumoto T, Senba M, Kanaya F, Mori N |
| Int J Oncol 2013 Oct;43(4):1176-86 |
| PMID 23857515 |
| X-linked inhibitor of apoptosis (XIAP) and XIAP-associated factor-1 expressions and their relationship to apoptosis in human hepatocellular carcinoma and non-cancerous liver tissues |
| Sakemi R, Yano H, Ogasawara S, Akiba J, Nakashima O, Fukahori S, Sata M, Kojiro M |
| Oncol Rep 2007 Jul;18(1):65-70 |
| PMID 17549347 |
| In vitro cytotoxicity of Artemisia vulgaris L |
| Saleh AM, Aljada A, Rizvi SA, Nasr A, Alaskar AS, Williams JD |
| essential oil is mediated by a mitochondria-dependent apoptosis in HL-60 leukemic cell line BMC Complement Altern Med |
| PMID 25002129 |
| Molecular evidence of Zn chelation of the procaspase activating compound B-PAC-1 in B cell lymphoma |
| Sarkar A, Balakrishnan K, Chen J, Patel V, Neelapu SS, McMurray JS, Gandhi V |
| Oncotarget 2016 Jan 19;7(3):3461-76 |
| PMID 26658105 |
| Elevated X-linked inhibitor of apoptosis protein (XIAP) expression uncovers detrimental prognosis in subgroups of neoadjuvant treated and T-cell rich esophageal adenocarcinoma |
| Schiffmann LM, Göbel H, Löser H, Schorn F, Werthenbach JP, Fuchs HF, Plum PS, Bludau M, Zander T, Schröder W, Bruns CJ, Kashkar H, Quaas A, Gebauer F |
| BMC Cancer 2019 May 31;19(1):531 |
| PMID 31151416 |
| Expression of X-linked inhibitor of apoptosis protein is a strong predictor of human prostate cancer recurrence |
| Seligson DB, Hongo F, Huerta-Yepez S, Mizutani Y, Miki T, Yu H, Horvath S, Chia D, Goodglick L, Bonavida B |
| Clin Cancer Res 2007 Oct 15;13(20):6056-63 |
| PMID 17947468 |
| Cisplatin induces apoptosis of hepatocellular carcinoma LM3 cells via down-regulation of XIAP |
| Shang MJ, Hong DF, Hu ZM, Zhang CW, Wu WD |
| Eur Rev Med Pharmacol Sci 2018 Jan;22(2):382-387 |
| PMID 29424923 |
| Octreotide enhances the sensitivity of the SKOV3/DDP ovarian cancer cell line to cisplatin chemotherapy in vitro |
| Shen Y, Ren M, Shi Y, Zhang Y, Cai Y |
| Exp Ther Med 2011 Nov;2(6):1171-1176 |
| PMID 22977639 |
| IAP family of cell death and signaling regulators |
| Silke J, Vucic D |
| Methods Enzymol 2014;545:35-65 |
| PMID 25065885 |
| l-asparaginase induces intrinsic mitochondrial-mediated apoptosis in human gastric adenocarcinoma cells and impedes tumor progression |
| Sindhu R, Manonmani HK |
| Biochem Biophys Res Commun 2018 Sep 18;503(4):2393-2399 |
| PMID 29966654 |
| IAPs: what's in a name? Mol Cell |
| Srinivasula SM, Ashwell JD |
| 2008 Apr 25;30(2):123-35 doi: 10 |
| PMID 18439892 |
| Evaluation of urinary XIAP as a diagnostic biomarker of carcinoma of urinary bladder |
| Srivastava AK, Singh PK, Singh D, Dalela D, Rath SK, Goel MM, Bhatt ML |
| Tumour Biol 2014 Aug;35(8):8243-8 |
| PMID 24852426 |
| MicroRNA-509-3p Inhibits Cancer Cell Proliferation and Migration via Upregulation of XIAP in Gastric Cancer Cells |
| Sun J, Li J, Zhang W, Zhang J, Sun S, Li G, Song H, Wan D |
| Oncol Res 2017 Mar 13;25(3):455-461 |
| PMID 27697095 |
| MicroRNA-149 suppresses the proliferation and increases the sensitivity of ovarian cancer cells to cisplatin by targeting X-linked inhibitor of apoptosis |
| Sun L, Zhai R, Zhang L, Zhao S |
| Oncol Lett 2018 May;15(5):7328-7334 |
| PMID 29731888 |
| A serine protease, HtrA2, is released from the mitochondria and interacts with XIAP, inducing cell death |
| Suzuki Y, Imai Y, Nakayama H, Takahashi K, Takio K, Takahashi R |
| Mol Cell 2001 Sep;8(3):613-21 |
| PMID 11583623 |
| Discovery of a Potent Nonpeptidomimetic, Small-Molecule Antagonist of Cellular Inhibitor of Apoptosis Protein 1 (cIAP1) and X-Linked Inhibitor of Apoptosis Protein (XIAP) |
| Tamanini E, Buck IM, Chessari G, Chiarparin E, Day JEH, Frederickson M, Griffiths-Jones CM, Hearn K, Heightman TD, Iqbal A, Johnson CN, Lewis EJ, Martins V, Peakman T, Reader M, Rich SJ, Ward GA, Williams PA, Wilsher NE |
| J Med Chem 2017 Jun 8;60(11):4611-4625 |
| PMID 28492317 |
| AEG-35156, an antisense oligonucleotide against X-linked inhibitor of apoptosis for the potential treatment of cancer |
| Tamm I |
| Curr Opin Investig Drugs 2008 Jun;9(6):638-46 |
| PMID 18516763 |
| Expression and prognostic significance of IAP-family genes in human cancers and myeloid leukemias |
| Tamm I, Kornblau SM, Segall H, Krajewski S, Welsh K, Kitada S, Scudiero DA, Tudor G, Qui YH, Monks A, Andreeff M, Reed JC |
| Clin Cancer Res 2000 May;6(5):1796-803 |
| PMID 10815900 |
| High expression levels of x-linked inhibitor of apoptosis protein and survivin correlate with poor overall survival in childhood de novo acute myeloid leukemia |
| Tamm I, Richter S, Oltersdorf D, Creutzig U, Harbott J, Scholz F, Karawajew L, Ludwig WD, Wuchter C |
| Clin Cancer Res 2004 Jun 1;10(11):3737-44 |
| X-linked inhibitor of apoptosis protein as a therapeutic target in metastatic melanoma |
| Tian F, Lee SW |
| J Invest Dermatol 2010 Sep;130(9):2169-72 |
| PMID 20711206 |
| High expression of XIAP and Bcl-2 may inhibit programmed cell death in glioblastomas |
| Tirapelli DPDC, Lustosa IL, Menezes SB, Franco IM, Rodrigues AR, Peria FM, Marinho AMDN, Serafini LN, Carlotti CG Jr, Tirapelli LF |
| Arq Neuropsiquiatr 2017 Dec;75(12):875-880 |
| PMID 29236891 |
| Expression and localization of inhibitor of apoptosis proteins in normal human tissues |
| Vischioni B, van der Valk P, Span SW, Kruyt FA, Rodriguez JA, Giaccone G |
| Hum Pathol 2006 Jan;37(1):78-86 |
| PMID 16360419 |
| A novel Cdk9 inhibitor preferentially targets tumor cells and synergizes with fludarabine |
| Walsby E, Pratt G, Shao H, Abbas AY, Fischer PM, Bradshaw TD, Brennan P, Fegan C, Wang S, Pepper C |
| Oncotarget 2014 Jan 30;5(2):375-85 |
| PMID 24495868 |
| Selective CDK7 inhibition with BS-181 suppresses cell proliferation and induces cell cycle arrest and apoptosis in gastric cancer |
| Wang BY, Liu QY, Cao J, Chen JW, Liu ZS |
| Drug Des Devel Ther 2016 Mar 16;10:1181-9 |
| PMID 27042010 |
| AP-1 confers resistance to anti-cancer therapy by activating XIAP |
| Wang Y, Wan GH, Wu YM, Wang HS, Wang HF, Zhang G, Lu LL, Li ZQ, Chan KY, Zhou Y, Cai SH, Qi YF, Du J |
| Oncotarget 2018 Jan 3;9(18):14124-14137 |
| PMID 29581832 |
| ARHI (DIRAS3)-mediated autophagy-associated cell death enhances chemosensitivity to cisplatin in ovarian cancer cell lines and xenografts |
| Washington MN, Suh G, Orozco AF, Sutton MN, Yang H, Wang Y, Mao W, Millward S, Ornelas A, Atkinson N, Liao W, Bast RC Jr, Lu Z |
| Cell Death Dis 2015 Aug 6;6:e1836 |
| PMID 26247722 |
| Down-regulation of XIAP enhances the radiosensitivity of esophageal cancer cells in vivo and in vitro |
| Wen X, Han XR, Fan SH, Zhang ZF, Chen L, Yi G, Wu DM, Lu J, Zheng YL |
| Biosci Rep 2017 Sep 19;37(5) |
| PMID 28821565 |
| Survivin and XIAP - two potential biological targets in follicular thyroid carcinoma |
| Werner TA, Dizdar L, Nolten I, Riemer JC, Mersch S, Schütte SC, Driemel C, Verde PE, Raba K, Topp SA, Schott M, Knoefel WT, Krieg A |
| Sci Rep 2017 Sep 12;7(1):11383 |
| PMID 28900184 |
| Survivin and XIAP: two valuable biomarkers in medullary thyroid carcinoma |
| Werner TA, Tamkan-Ölcek Y, Dizdar L, Riemer JC, Wolf A, Cupisti K, Verde PE, Knoefel WT, Krieg A |
| Br J Cancer 2016 Feb 16;114(4):427-34 |
| PMID 26882066 |
| Prosurvival function of the cellular apoptosis susceptibility/importin-α1 transport cycle is repressed by p53 in liver cancer |
| Winkler J, Ori A, Holzer K, Sticht C, Dauch D, Eiteneuer EM, Pinna F, Geffers R, Ehemann V, Andres-Pons A, Breuhahn K, Longerich T, Bermejo JL, Gretz N, Zender L, Schirmacher P, Beck M, Singer S |
| Hepatology 2014 Sep;60(3):884-95 |
| PMID 24799195 |
| Immunohistochemical detection of X-linked inhibitor of apoptosis (XIAP) in neoplastic and other thyroid disorders |
| Xiao GQ, Unger PD, Burstein DE |
| Ann Diagn Pathol 2007 Aug;11(4):235-40 |
| PMID 17630106 |
| XIAP, a cellular member of the inhibitor of apoptosis protein family, links the receptors to TAB1-TAK1 in the BMP signaling pathway |
| Yamaguchi K, Nagai S, Ninomiya-Tsuji J, Nishita M, Tamai K, Irie K, Ueno N, Nishida E, Shibuya H, Matsumoto K |
| EMBO J 1999 Jan 4;18(1):179-87 |
| PMID 9878061 |
| Artemisia capillaris extract AC68 induces apoptosis of hepatocellular carcinoma by blocking the PI3K/AKT pathway |
| Yan H, Jung KH, Kim J, Rumman M, Oh MS, Hong SS |
| Biomed Pharmacother 2018 Feb;98:134-141 |
| PMID 29253760 |
| Disturbed balance of expression between XIAP and Smac/DIABLO during tumour progression in renal cell carcinomas |
| Yan Y, Mahotka C, Heikaus S, Shibata T, Wethkamp N, Liebmann J, Suschek CV, Guo Y, Gabbert HE, Gerharz CD, Ramp U |
| Br J Cancer 2004 Oct 4;91(7):1349-57 |
| PMID 15328523 |
| The anti-cancer activity of Antrodia camphorata against human ovarian carcinoma (SKOV-3) cells via modulation of HER-2/neu signaling pathway |
| Yang HL, Lin KY, Juan YC, Kumar KJ, Way TD, Shen PC, Chen SC, Hseu YC |
| J Ethnopharmacol 2013 Jun 21;148(1):254-65 |
| PMID 23619020 |
| Butein Shows Cytotoxic Effects and Induces Apoptosis in Human Ovarian Cancer Cells |
| Yang PY, Hu DN, Lin IC, Liu FS |
| Am J Chin Med 2015;43(4):769-82 |
| PMID 26119952 |
| XIAP underlies apoptosis resistance of renal cell carcinoma cells |
| Yang WZ, Zhou H, Yan Y |
| Mol Med Rep 2018 Jan;17(1):125-130 |
| PMID 29115633 |
| XIAP is a predictor of cisplatin-based chemotherapy response and prognosis for patients with advanced head and neck cancer |
| Yang XH, Feng ZE, Yan M, Hanada S, Zuo H, Yang CZ, Han ZG, Guo W, Chen WT, Zhang P |
| PLoS One 2012;7(3):e31601 |
| PMID 22403616 |
| Co-expression of XIAP and CIAP1 Play Synergistic Effect on Patient's Prognosis in Head and Neck Cancer |
| Yang XH, Liu L, Hu YJ, Zhang P, Hu QG |
| Pathol Oncol Res 2019 Jul;25(3):1111-1116 |
| PMID 30421089 |
| Role of Smac, survivin, XIAP, and Omi/HtrA2 proteins in determining the chemotherapeutic response of patients with cervical cancer treated with neoadjuvant chemotherapy |
| Ye T, Yao H, Xu Y, Zhao X, Lu H, Zhang R |
| Cancer Biomark 2019;26(3):249-259 |
| PMID 31356194 |
| Association between expression of X-linked inhibitor of apoptosis protein and the clinical outcome in a BRAF V600E-prevalent papillary thyroid cancer population |
| Yim JH, Kim WG, Jeon MJ, Han JM, Kim TY, Yoon JH, Hong SJ, Song DE, Gong G, Shong YK, Kim WB |
| Thyroid 2014 Apr;24(4):689-94 |
| PMID 24124924 |
| Xanthohumol induces growth inhibition and apoptosis in ca ski human cervical cancer cells |
| Yong WK, Abd Malek SN |
| Evid Based Complement Alternat Med 2015;2015:921306 |
| PMID 25949267 |
| XIAP overexpression promotes bladder cancer invasion in vitro and lung metastasis in vivo via enhancing nucleolin-mediated Rho-GDIβ mRNA stability |
| Yu Y, Jin H, Xu J, Gu J, Li X, Xie Q, Huang H, Li J, Tian Z, Jiang G, Chen C, He F, Wu XR, Huang C |
| Int J Cancer 2018 May 15;142(10):2040-2055 |
| PMID 29250796 |
| Systems analysis of apoptotic priming in ovarian cancer identifies vulnerabilities and predictors of drug response |
| Zervantonakis IK, Iavarone C, Chen HY, Selfors LM, Palakurthi S, Liu JF, Drapkin R, Matulonis U, Leverson JD, Sampath D, Mills GB, Brugge JS |
| Nat Commun 2017 Aug 28;8(1):365 |
| PMID 28848242 |
| Inhibition of MDM2 by nilotinib contributes to cytotoxicity in both Philadelphia-positive and negative acute lymphoblastic leukemia |
| Zhang H, Gu L, Liu T, Chiang KY, Zhou M |
| PLoS One 2014 Jun 26;9(6):e100960 |
| PMID 24968304 |
| 10H-3,6-Diazaphenothiazine induces G(2)/M phase cell cycle arrest and caspase-dependent apoptosis and inhibits cell invasion of A2780 ovarian carcinoma cells through the regulation of NF-κB and (BIRC6-XIAP) complexes |
| Zhang J, Ming C, Zhang W, Okechukwu PN, Morak-Mńodawska B, Pluta K, Jeleń M, Akim AM, Ang KP, Ooi KK |
| Drug Des Devel Ther 2017 Oct 24;11:3045-3063 |
| PMID 29123378 |
| XIAP is highly expressed in esophageal cancer and its downregulation by RNAi sensitizes esophageal carcinoma cell lines to chemotherapeutics |
| Zhang S, Ding F, Luo A, Chen A, Yu Z, Ren S, Liu Z, Zhang L |
| Cancer Biol Ther 2007 Jun;6(6):973-80 |
| PMID 17611394 |
| A new brominated chalcone derivative suppresses the growth of gastric cancer cells in vitro and in vivo involving ROS mediated up-regulation of DR5 and 4 expression and apoptosis |
| Zhang S, Li T, Zhang Y, Xu H, Li Y, Zi X, Yu H, Li J, Jin CY, Liu HM |
| Toxicol Appl Pharmacol 2016 Oct 15;309:77-86 |
| PMID 27594528 |
| Prognostic significance of XIAP and NF-κB expression in esophageal carcinoma with postoperative radiotherapy |
| Zhou S, Ye W, Shao Q, Qi Y, Zhang M, Liang J |
| World J Surg Oncol 2013 Nov 5;11:288 |
| PMID 24188482 |
| Tumor suppressor XAF1 induces apoptosis, inhibits angiogenesis and inhibits tumor growth in hepatocellular carcinoma |
| Zhu LM, Shi DM, Dai Q, Cheng XJ, Yao WY, Sun PH, Ding Y, Qiao MM, Wu YL, Jiang SH, Tu SP |
| Oncotarget 2014 Jul 30;5(14):5403-15 |
| PMID 24980821 |
| Concomitance of downregulated active caspase-3 and upregulated X-chromosome linked inhibitor of apoptosis protein as a sensitive diagnostic approach for breast cancer |
| Zohny SF, Zamzami MA, El-Shinawi M |
| Mol Cell Biochem 2019 May;455(1-2):159-167 |
| PMID 30446907 |
| Citation |
| This paper should be referenced as such : |
| Catarina Sofia Reis Silva, Gabriel Henrique Barbosa, Paola Cristina Branco, Paula Christine Jimenez, Joo Agostinho Machado-Neto, Letcia Veras Costa-Lotufo |
| XIAP (X-linked inhibitor of apoptosis) |
| Atlas Genet Cytogenet Oncol Haematol. 2020;24(11):424-443. |
| Free journal version : [ pdf ] [ DOI ] |
| Other Leukemias implicated (Data extracted from papers in the Atlas) [ 3 ] |
|
t(X;12)(q25;p13) OLR1/XIAP
t(X;12)(q25;p13) TMEM52B/XIAP t(X;12)(q25;p13) XIAP/OLR1 |
| Other Cancer prone implicated (Data extracted from papers in the Atlas) [ 1 ] |
| X-linked lymphoproliferative disease (XLP) |
| External links |
| REVIEW articles | automatic search in PubMed |
| Last year publications | automatic search in PubMed |
| © Atlas of Genetics and Cytogenetics in Oncology and Haematology | indexed on : Fri Feb 19 18:02:57 CET 2021 |
For comments and suggestions or contributions, please contact us